In the hard news business, it is well understood that if it bleeds, it leads. In cultural news, the same principle applies. Not a day goes by that we dont see a story of a panel discussion in jeopardy or cancelled, a controversial film withdrawn, or an academic on the incorrect side of a cultural debate de-platformed. One could be forgiven for assuming that cancel culture reigns supreme in the public forum.

Its gratifying, therefore, to report that a speaking engagement featuring a highly controversial researcher and clinician in the hot-button field of gender dysphoria will take place as planned at McGill University. The cancel-culture mould in this case was not broken by chance. A good strategic plan prevented a predictable brush fire of protest from becoming a conflagration.

Within the Department of Psychiatry at McGill University, the Division of Social and Transcultural Psychiatry (DSTP) pursues and promotes research, training and consultation in the domains of social and cultural psychiatry. Under the rubric of the Culture, Mind and Brain Program, an ongoing sub-division of the DSTP, with links to affiliated faculty in other McGill departments and worldwide, the DSTP is presenting a lecture, titled Children and Adolescents with Gender Dysphoria: Some contemporary research and clinical issues, to be delivered Jan. 23 by Dr. Ken Zucker, professor of psychiatry at the University of Toronto.

The cancel-culture mould in this case was not broken by chance

Dr. Zucker, a pioneer and leading expert in the field of gender dysphoria, is a cancel-culture veteran, and remains a magnet for trans activists ire. In 2015, when he headed up the Gender Identity Clinic at Torontos Centre for Addiction and Mental Health (CAMH), a post hed held for decades, he was targeted for condemnation by trans activists, who accused him of practicing conversion therapy, a false allegation that led to his summary dismissal. Dr. Zucker successfully refuted the charge in a later lawsuit against CAMH, resulting in a payout and retractions, but not in reinstatement. Dr. Zucker does in fact endorse supervised hormone therapy where warranted for adolescents on a case-by-case basis, but is a proponent of watchful waiting and for treating patients holistically.

DSTP Professor Samuel Veissire, organizer of this event, has been keeping me up to date on responses. To be honest, when I received his invitation to the talk and I saw Dr. Zuckers name, I entered it into my calendar with a question mark. I assumed the odds were high that he would be de-platformed by an administration browbeaten by activists. Im happy to be proven wrong.

Thats not to say there was no opposition. Queer McGill issued a warning on its Facebook page, repeating the canard about conversion therapy and advising friends that the talk would be given from a non-trans perspective. Prof. Veissire made a point of meeting with Queer McGill to hear their complaints and concern. Their position was basically no conversation without us at first, but he argued persuasively and respectfully that it is also reasonable for parents to assume their right and to honour their responsibility to be involved in decisions around radical physical changes in their children. This outreach in itself, letting people who object to the talk know that their perspectives are welcome in the conversation, I imagine went some distance in calming potentially roiled waters.

The Facebook pages comments were refreshingly diverse, and maturely considered. One queer woman of colour posted, I understand that this talk isnt for everyone, but I feel like we tend to be quick on condemning what we perceive like an attack, and police each other instead of practicing patience with different levels of understanding or even taking the opportunity to speak our truth.

Prof. Veissire also sent out a call for support on a sex research email list. Other scholars then shared it on Twitter. Responses were intended for both the administration at McGill and the public record, to show people or groups who had asked for the talk to be cancelled that there was widespread support for Dr. Zucker.

The Facebook page's comments were refreshingly diverse

Letters attesting to Dr. Zuckers eminence in his field flowed in from authoritative colleagues, such as Northwestern University psychology professor J. Michael Bailey, Columbia Universitys Developmental Psychoendocrinology Program director Heino F. L. Meyer-Bahlburg, University of Toronto psychiatry professor Ray Blanchard, and Harvard University psychology professor Steven Pinker.

Most touching was an ardent testimonial from Pique Resilience Project, a support group for detransitioned women. They wrote that they themselves would greatly have benefited from the more careful, evidence-based treatment approach that Dr. Zucker uses in his clinical practice. Their email concludes, Perspectives like Dr. Zuckers are critical to ensuring that more individuals dont make the mistake we did.

Most people, Prof. Veissire believes, want to see more brave conversations on difficult topics, but are reluctant to be publicly associated with politically unorthodox views. His private conversations with students have convinced him that when they see evidence that other people they trust are also open to these conversations, peoples fears ease up a bit.

Perhaps, as Prof. Veissire mused, 2020 will be the year of reason in the culture wars spin. Perhaps. Just minutes before filing this column, I was made aware that the Pride Therapy Network of Montreal had sent a letter dated Jan. 20 to Prof. Veissires asking that Dr. Zucker be de-platformed. And on Wednesday McGills Joint Board-Senate Subcommittee on Queer People also wrote the organizers to express disappointment and ask that the event be cancelled. It wont be. A more constructive approach would be for their members to attend the presentation and contribute their perspectives to the discussion in a civil fashion.

Email: kaybarb@gmail.com | Twitter:

Link:
Barbara Kay: Will 2020 will be the year of reason in the cancel-culture wars? - National Post

Recommendation and review posted by Bethany Smith

Stem cell banking or preservation is a combined process of extraction, processing and storage of stem cells, so that they may be used for treatment of various medical conditions in the future, when required. Stem cells have the amazing power to get transformed into any tissue or organ in the body. In recent days, stem cells are used to treat variety of life-threatening diseases such as blood and bone marrow diseases, blood cancers, and immune disorders among others.

The market of stem cell banking is anticipated to grow with a significant rate in the coming years, owing to factors such as, development of novel technologies for stem cell preservation and processing, and storage; growing awareness on the potential of stem cells for various therapeutic conditions. Moreover, increasing investments in stem cell research is also expected to propel the growth of the stem cell banking market across the globe. On other hand rising burden of major diseases and emerging economies are expected to offer significant growth opportunities for the players operating in stem cell banking market.

Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPBT00002082/

The key players influencing the market are:

Cordlife, ViaCord (A Subsidiary of PerkinElmer), Cryo-Save AG, StemCyte India Therapeutics Pvt. Ltd., Cryo-Cell International, Inc., SMART CELLS PLUS, Vita 34, LifeCell, Global Cord Blood Corporation, CBR Systems, Inc.

This report contains:

The global stem cell banking market is segmented on the basis of source, service type, and application. The source segment includes, placental stem cells (PSCS), dental pulp-derived stem cells (DPSCS), bone marrow-derived stem cells (BMSCS), adipose tissue-derived stem cells (ADSCS), human embryo-derived stem cells (HESCS), and other stem cell sources. Based on service type the market is segmented into, sample processing, sample analysis, sample preservation and storage, sample collection and transportation. Based on application, the market is segmented as, clinical applications, research applications, and personalized banking applications.

Stem Cell Banking Market Global Analysis to 2027 is an expert compiled study which provides a holistic view of the market covering current trends and future scope with respect to product/service, the report also covers competitive analysis to understand the presence of key vendors in the companies by analyzing their product/services, key financial facts, details SWOT analysis and key development in last three years. Further chapter such as industry landscape and competitive landscape provides the reader with recent company level insights covering mergers and acquisitions, joint ventures, collaborations, new product developments/strategies taking place across the ecosystem. The chapters also evaluate the key vendors by mapping all the relevant products and services to exhibit the ranking/ position of top 5 key vendors.

Stem Cell Banking Market is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2018 2027, considering 2018 as the base year and 2018 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Report Spotlights

Purchase This Report @ https://www.theinsightpartners.com/buy/TIPBT00002082/

About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Go here to see the original:
Stem Cell Banking Market smart Strategies of the Research and Development Process Dagoretti News - Dagoretti News

Recommendation and review posted by Bethany Smith

Eric Stegers heart is full, although his liver is smaller by 60%.

Steger, a 50-year-old man from Sunnydale, California, affiliated with Chabad, was in Pittsburgh earlier this month fulfilling his dream of donating an entire lobe of his liver to help save the life of another.

The liver recipient, Conservative Rabbi Jeffrey Kurtz-Lendner, 53, said he feels like he has been given a second chance at life.

Get The Jewish Chronicle Weekly Edition by email and never miss our top storiesFree Sign Up

Kurtz-Lendner, who relocated to Pittsburgh from Iowa for the purpose of obtaining a transplant at UPMC, had been diagnosed with fatty liver cirrhosis, but the doctors did not know how serious it was until they were in the midst of the transplant.

I could have died before I got put onto a list, said Kurtz-Lendner, who, after the Jan. 7 surgery, is still recuperating but has been discharged from the hospital.

Steger, a math tutor at Foothill College in Northern California, has donated stem cells for a bone marrow transplant and platelets many times, and has been wanting to help save a life with one of his organs for years. He even traveled to Israel to donate a kidney, but was ultimately turned down because he had hypertension.

About a year ago, though, he saw a UPMC commercial airing in California that advertised the fact that it was now performing altruistic liver donations.

I decided to give it a try, said Steger.

He then got in touch with Chaya Lipschutz, an Orthodox woman from Brooklyn who donated a kidney to a stranger in 2005, and since then has made it her work to help others find kidney matches. She receives no money for her services.

Lipschutz had made the shidduch with the kidney patient in Israel for Steger that did not work out, he said.

As fate would have it, Lipschutz did know people who needed a live liver transplant. Steger was medically cleared for the procedure, but the first few people with whom he matched found other donors. Lipschutz then turned to message boards to post that she had an able and willing donor.

Now I was a solution in search of a problem, said Steger.

When Kurtz-Lendners sister in Teaneck, New Jersey, happened to see Lipschutzs post, the match was made.

Post-surgery, both donor and recipient are doing well.

Im feeling very positive, said Kurtz-Lendner, noting that full recovery from the procedure will take about a year. Two weeks ago, I was dying. Now, I have another 30 years.

He, his wife Robin, and his oldest daughter will remain in Pittsburgh for at least six months.

Kurtz-Lendner did not meet Steger until after the surgery, and sees him as an inspiration of a human being. I appreciate what he has done. He just saved my life.

Steger returned to California this week. During his time in Pittsburgh, he received warm hospitality from the citys Jewish community, particularly the Bikur Cholim of Pittsburgh, run by Nina Butler, he said.

Patients and families who come here from out of town always remind us of how special our community is, said Butler. As the Bikur Cholim of Pittsburgh, Im simply organizing the generosity of volunteers to provide the specific support that each patient wants. That started before Jeff or Eric arrived, answering their questions about housing, Shabbat observance and kosher food.

Eric is observant and came unaccompanied, so his housing was complicated because the Family House does not allow patients to stay completely alone, Butler explained. We provided home hospitality, and we also organized volunteers to drop off meals for Eric while his hosts were at work. Most of all, we formed relationships with both patients and Jeffs family so they knew there were Pittsburghers who had their backs.

Robin Kurtz-Lendner said that she and her husband felt so supported, even before we got here. Its been incredible. The whole community has been rallying around us and its really been appreciated.

Donating part of his liver was not easy, Steger acknowledged. Still, he wants to encourage others to consider organ donation.

Im not going to sugarcoat it, he said. It was the hardest thing Ive ever done. It was a year out of my life, one full year when I was thinking about this all the time.

There was a battery of tests, the surgery itself, and now the recovery phase, he said, which all carry physical and emotional risks.

But he is hoping what he did will help generate continued interest in organ donation.

I hope my experience will inspire other people to investigate it for themselves, he said.pjc

Toby Tabachnick can be reached atttabachnick@pittsburghjewishchronicle.org.

View post:
California man donates part of his liver to Conservative rabbi in Pittsburgh - The Australian Jewish News

Recommendation and review posted by Bethany Smith

New Delhi: On Saturday, January 18th, 2020, the Advancells Group & the International Fertility Center together ended their first workshop Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020). The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing & processes and IFC, one of Indias most prestigious Fertility institute who were joined by candidates with MBBS/BAMS/BHMS/BPharma & Masters degree in Life Sciences.

The key-note speaker of the workshop was Dr. Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event. Participants also had a privilege to listen to Dr. Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual & kit-based models to help the candidates gain exposure.

Dr. Punit Prabha, Head of Clinical Research and Dr. Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist. With the help of detailed analysis of Application of PRP for Skin rejuvenation; Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue; and Cell Culturing and Expansion in a Laboratory, applicants understood the application of stem cells in aesthetics, cosmetology, and anti-aging.

Vipul Jain, Founder & CEO of Advancells Group said, Educating young scientists about stem cells is important for us. With this workshop we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers. We wanted to establish more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020), its hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Advancells Group Advancells is leading the field of stem cell therapies in India and abroad, with representative offices in Bangladesh and Australia. The company provides arrangements for stem cell banking and protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. With a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. Advancells also intends to file a patent for this processing technology soon.

For more information, visit https://www.advancells.com/

International Fertility Centre IFC is Indias leading fertility center under the leadership and guidance of Dr. Rita Bakshi. She along with her solid team of experienced doctors have create a network of 10+ IVF clinics located in India and Nepal. Their services include In-vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Injection (ICSI), Egg Donation, Surrogacy, Blastocyst, Assisted Hatching, Hysteroscopy, Laparoscopy and much more.

Original post:
Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - India Education Diary

Recommendation and review posted by Bethany Smith

New cell treatment could help maintain healthy blood sugar levels

A new cell treatment to enhance islet transplantation could help maintain healthy blood sugar levels in Type 1 diabetes without the need for multiple transplants of insulin producing cells or regular insulin injections, research suggests.

In Type 1 diabetes the insulin-producing cells of the pancreas are destroyed. Insulin injections maintain health but blood glucose levels can be difficult to control. Currently in the UK it is estimated that approximately 400,000 people in the UK have type 1 diabetes.

The current recommendation for people with type 1 diabetes who have lost awareness of low blood glucose levels is the transplantation of islets the insulin producing part of the pancreas.

A study in mice found that transplanting a combination of islets with connective tissue cells found in umbilical cords known as stromal cells - could potentially reduce the number of pancreases required for the procedure.

Mice that received the islet-stromal cell combination were found to have better control of blood glucose and less evidence of rejection of islets after seven weeks, compared to those that received islets alone.

In humans, more than two donor pancreases, which are scarce, are often needed because islets can be rejected and are slow to form new blood supplies.

Therefore, multiple islet transplantations and anti-rejection medication are required to control blood sugar levels in people with Type 1 diabetes. Scientists at the University of Edinburgh hope their findings could be a way of overcoming these issues.

The researchers found that islets combined with stromal cells successfully returned normal blood glucose levels just three days after transplantation.

Other studies have used cells sourced from bone marrow and fat. This is the first to use stem cells from umbilical cords and has produced superior results.

The research is published in the journal Science Translational Medicine and funded by Chief Scientist Office in Scotland and Diabetes UK.

Shareen Forbes, Professor of Diabetic Medicine at the University of Edinburgh and Lead Physician for the Islet Transplant Program in Scotland, said: Should this research prove successful in humans, we could reduce the number of islets needed to control blood sugar levels using this co-transplantation approach. This would mean more people with Type 1 diabetes could be treated using islet transplantation while significantly reducing the waiting time on the transplant list.

John Campbell, Professor and Associate Director Tissues, Cells & Advanced Therapeutics at the Scottish National Blood Transfusion Service has said that further work is needed to establish the long-term safety of using this type of stromal cell in this setting before proceeding to clinical trials in humans.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK, said: Islet transplants have been life changing for some people with Type 1 diabetes, treating dangerous hypo unawareness. But there currently arent enough donated pancreases to go around, and the procedure itself isnt yet as effective as it could be.

This new research from the University of Edinburgh is a promising step forward, and one we hope will lead to islet transplants becoming both more effective and more widely available in the future.

Register for your free SelectScience membership today to receive the latest editorial articles and technology news direct to your inbox>>

View original post here:
Cell therapy trialed in mice offers diabetes treatment hope - SelectScience

Recommendation and review posted by Bethany Smith

Debuts at the NY20 Foundation for Podiatric Medicine Meeting

HACKENSACK, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Royal Biologics, an ortho-biologics company specializing in the research and advancement of novel ortho-biologics solutions, today announced the launch of Cryo-Cord, the first DMSO-free viable umbilical cord graft. The company will be showcasing Cryo-Cord along with its new portfolio of Autologous Live Cellular (ALC) technologies at the NY20 Foundation for Podiatric Medicine meeting, held January 24-26 in New York, NY for more than 1500 clinical attendees.

The company will feature its full suite of surgical biologic offerings at exhibit booth #322, and on the podium for Innovation Theater presentations at 10:30am on Friday 1/24/20 and 12pm on Saturday 1/25/20. These scientific presentations will feature several products within the Royal Biologics portfolio. At its booth, Royal Biologics will showcase its comprehensive ALC portfolio designed to personalize live regenerative healing for a wide variety of wound types across the orthopedics continuum.

The launch of Cryo-Cord enables providers with the first DMSO-free viable umbilical cord tissue. Cryo-Cord has been obtained with consent from healthy mothers during cesarean section delivery and is intended for use as a soft tissue barrier or wound dressing. Cryo-Cord is processed using aseptic techniques and frozen with a proprietary cryoprotectant.

Cryo-Cord offers a new enhancement to traditional wound care therapies and we are excited to pave the way with the first DMSO-free cryoprotectant graft on the market, said Salvatore Leo, Chief Executive Officer of Royal Biologics.

Other featured products at NY20 will include Maxx-Cell, which was launched as the world's most advanced bone marrow aspiration device. Maxx-Cell offers a new technique to a gold standard approach of aspirating a patients autologous bone marrow cells. Maxx-Cell however does not require centrifugation to deliver a final end product. The Maxx-Cell system maximizes stem and progenitor cell yields by giving the surgeon the ability to efficiently harvest bone marrow from multiple levels within the medullary space, while restricting dilution of peripheral blood. As a result, Maxx-Cell delivers a high, most pure enriched form of bone marrow aspirate without the need for centrifugation.

This month, the company has also announced the launch of MAGNUS, which is a DMSO-free viable cellular bone allograft and demos will be available during the conference. MAGNUS presents a unique solution to traditional viable cellular allograft technology as it utilizes a DMSO-free cryoprotectant. This novel approach to the viable cellular allograft market differentiates MAGNUS from other technologies currently available.

Leo added, We are excited to participate in NY20 and share how our Autologous Live Cellular based therapies give the surgeons an efficient and effective way to enhance surgical outcomes by providing alternatives to conventional therapies for bone and soft tissue related injuries. We also believe that in a cost-conscious industry, we can provide novel viable cellular products that provide value at the point of care.

To watch the latest ALC product videos and learn more about the range of regenerative medical products offered by Royal Biologics, along with a schedule of 2020 conferences, visit http://www.RoyalBiologics.com.

About Royal Biologics

Royal Biologics is an ortho-biologics company specializing in the research and advancement of Regenerative Cellular Therapy. Its primary focus is on using autologous bioactive cells to help promote healing in a wide range of clinical settings, with its portfolio of FDA-approved medical devices. For more information on its line of products, visit http://www.royalbiologics.com.

For more media information, contact:Lisa Hendrickson, LCH Communicationslisa@lchcommunications.com516-767-8390

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ee412ed7-d46b-40b7-9322-a65f5cb26430

Go here to see the original:
Royal Biologics Announces the Launch of Cryo-Cord, the First Non-DMSO Viable Umbilical Cord Graft - Yahoo Finance

Recommendation and review posted by Bethany Smith

NEW YORK and LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will present at the 10th Annual California ALS Research Summit, January 24-25 at Cedars-Sinai Medical Center, Los Angeles, California.

Dr. Kern will provide an update on BrainStorms Phase 3 ALS Clinical Trial on Friday, January 24, 10:30 -11:10 AM PT, during the session: CIRM funded Stem Cell Clinical Trials in California Updates.

Dr. Kern stated, This prestigious Summit works to increase, expedite and promote the amount and level of amyotrophic lateral sclerosis (ALS) research done in California that has been reinforced and amplified by the international ALS scientific and medical community. I am pleased to have the opportunity to share all that BrainStorm has accomplished in our fully enrolled Phase 3 clinical trial of NurOwn(NCT03280056).

Chaim Lebovits, President and CEO of BrainStorm, stated, California continues to be a global leader in stem cell research and scientific funding. Due to Californias commitment to stem cell scientific investigation, BrainStorm is at an inflection point as we bring our investigational therapy, NurOwn, toward the submission of a biological license application. In July 2017, BrainStorm was awarded a grant of $15.9 million from the California Institute for Regenerative Medicine (CIRM) and three of Californias most prestigious medical centers: University of California, Irvine, Cedars-Sinai Medical Center, and California Pacific Medical Center have contributed immensely to advancement of NurOwn. Everyone at BrainStorm is proud Dr. Kern will have the opportunity to present to the ALS community of California all that has been accomplished due to their ongoing support and encouragement.

About The California ALS Research Summit:

The California ALS Research Summit is the tenth annual gathering of researchers, investigators, clinicians, biotech companies, government representatives, partner organizations, and advocates in ALS and related fields in the State of California.

The purpose of the Summit is to help increase, expedite and promote the amount and level of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's Disease) and related research done in California; and to foster networking, collaboration and cooperation among investigators, their peers and their colleagues to identify, develop and deliver new and effective treatments, ideas and, ultimately, cures for ALS.

The result of our efforts is an ongoing roadmap for ALS research in California, which will provide the basis for partnering within the state and other supporters to further studies to find new treatments and ultimately a cure for the disease.

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at http://www.brainstorm-cell.com.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Or:Katie GallagherLaVoieHealthSciencesPhone: + 1 617-374-8800 x109kgallagher@lavoiehealthscience.com

Original post:
BrainStorm Cell Therapeutics COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit - Yahoo Finance

Recommendation and review posted by Bethany Smith

Janssen has announced that the European Commission (EC) has grantedmarketing authorisationfora new Darzalex (daratumumab) combo, for newly diagnosed, transplant eligible patients with multiple myeloma (MM).

On the news, the combination, which consists of the biologic combined with bortezomib, thalidomide and dexamethasone(VTd) is now the first regimen approved in over six years for newly diagnosed patients who are eligible for a stem cell transplant. It also means that the patient population now has their first opportunity to be treated with a monoclonal antibody.

The company says that the approval was based on results from part one of the Phase III CASSIOPEIA (MMY3006) study, which showed that after consolidation, the stringent complete response (sCR) rate was 9% higher in the Darzalex-VTd arm than the VTd alone arm.

Further, at a median follow-up of 18.8 months, PFS was significantly improved in the Darzalex-VTd group, with the addition of the drug resulting in an 18-month PFS rate of 93%, compared to 85% for VTd alone.

The effectiveness of first line treatment is critical to maximise time until relapse, explained Philippe Moreau, principal investigator and Head of the Haematology Department at the University Hospital of Nantes.

He continued, The CASSIOPEIA study answered that question definitively, demonstrating that the addition of Darzalex in combination with VTd can lead to very deep remissions and also prolong PFS. Im pleased to see the European Commission have recognised this as well.

MM is an incurable blood cancer that starts in the bone marrow and is characterised by an excessive proliferation of plasma cells. In Europe, more than 48,200 people were diagnosed with MM in 2018, with more than 30,800 deaths related to the disease.

Visit link:
Darzalex EU nod marks first newly diagnosed MM treatment in six years - PharmaTimes

Recommendation and review posted by Bethany Smith

In November 2018, Chinese biophysics researcher He Jiankuimade a historic announcement.

Two twin girls nicknamed Lulu and Nana had become the worlds first genetically modified human beings.

Using a gene-editing technology known as CRISPR, He had manipulated the DNA of the embryos that would become the girls in an effort to make them immune to the HIV virus.

What first seemed like a historic triumph of science, however, quickly became one of the most infamous scandals in medical history.

The researcher was swiftly fired from his university, put under police investigation, and denounced by experts around the world who said he jumped the gun and carried out an experiment that was unsafe and unethical.

In December, He was sentenced to three years in prison for illegally carrying out human embryo gene-editing intended for reproduction. Its unclear whether the experiment caused any genetic damage to Lulu and Nana or if they are even resistant to the HIV virus.

Kiran Musunuru, one of the worlds foremost genetics researchers, was the first expert to publically condemn Hes experiment.

Nonetheless, Musunuru says the birth of the Chinese twins marks the beginning of a new human era, the possibilities of which are boundless.

Potential future implications of gene-editing technology range from preventing genetic diseases to producing designer babies with custom traits to creating superhumans and controlling our own evolution.

With the release of his new book, The CRISPR Generation: The story of the Worls First Gene-Edited Babies, The Globe Posts Bryan Bowmanspoke to Musunuru about where this technology could go from here and what it could mean for the future of humanity.

The following interview is lightly condensed and edited for length and clarity.

Bowman: Could you explain what CRISPR is broadly and how that technology evolved to where it is today?

Musunuru: CRISPR is one type of gene-editing tool. Gene editing is a technology that allows us to make changes to genes in the DNA and in the cells in the body. If were talking about human beings, typically were talking about changes that are related to health or disease.

There are several types of gene editing tools, but CRISPR is by far the most popular one. CRISPR is interesting because it wasnt invented. It actually exists naturally in all sorts of bacteria. It evolved as a sort of an immune system that can fight off viral infections. Just like we can get viral infections, it turns out bacteria can get viral infections as well. And so bacteria created a system by which they can fight off viruses. So thats where CRISPR came from.

Over the past couple of decades, a variety of very talented scientists identified it, discovered it in bacteria, and then were able to adapt it into a gene-editing tool that can now be used in human cells.

What we can do with CRISPR is either turn off genes and thats easier to do or we can make more precise changes to genes such as correcting a mutation that causes disease.

Bowman: Last year, there was the famous or infamous case where Dr. He Jiankui in China covertly created the first gene-edited babies. And I understand that you were the first expert to publicly condemn the experiment. What exactly did Dr. He do and why did you feel it was so unethical?

Musunuru: What he was trying to do was use CRISPR to turn off a gene called CCR5. By turning off this gene, he was hoping to make the babies that were born resistant to HIV infection, HIV being the virus that causes AIDS.

There are many people who are naturally born with this chain turned off and theyre resistant to HIV. So the rationale was, well, Im going to try to create babies who have the same trait.

What he did was problematic for two reasons. One, it was, to put it lightly, a scientific disaster. Everything you worry about going badly with CRISPR actually did happen. Any technology has a potential for a lot of good with the potential for bad. I compare it to fire. It can be very useful. But if youre not careful, it can cause wildfires and a lot of damage and hurt a lot of people. Its the same with CRISPR. It can do a lot of good. It can help patients who have bad diseases. But if youre irresponsible with it, it could actually cause unintended genetic damage.

Its not clear whether these kids that were born they were twin girls nicknamed Lulu and Nana its not clear whether theyre actually protected against HIV infection. Its not clear whether they might have suffered some genetic damage that might have health consequences for them. Its not clear whether the genetic damage if it did occur could get passed down to their children and affect future generations.

So scientifically, there are a lot of problems with it. The work was very premature. I would say that if we were ever going to do this in a reasonable, rational, safe way, were years away from doing it. But he went ahead and just did it anyway. You can call him a rogue scientist, as clich as it is. And he did it in conditions of secrecy. There was essentially no oversight. And potentially these twins and future generations might suffer the consequences.

The other problem is a problem of ethics. The way in which he did it basically violated every principle of ethical medical research in the textbook. Basically, everything that you could do wrong, he did it wrong.

Whenever we do an experimental procedure, we hope that the benefits greatly outweigh the risks. What he was trying to do was protect these kids from HIV. But the truth is, they were in no particular danger of getting HIV compared to the average person. In China, the prevalence of HIV is about 0.1 percent. So there wasnt really much for them to gain. Even if they did somehow during their lifetime get the HIV infection, we have good treatments to prevent it from proceeding to full-blown AIDS.

So what was the benefit of doing this procedure? You have to balance that against the harms. And the genetic damage thats possible that raises risks of things like cancer and heart disease and other diseases. When you have those risks and very little benefit, then its just not a favorable ratio. And thats intrinsically unethical.

Bowman: Seeing as you said that were years away from doing something like this in a more responsible and ethical way, what are the greatest challenges to getting to a point where parents will have the option to go forth with a gene-editing procedure that might prevent their children from suffering from some kind of genetic disease?

Musunuru: There are really two aspects to this. One is a scientific or medical aspect. Can we get to a place where gene-editing of embryos is well-controlled? Where we know that what were doing is truly safe and appropriate from that perspective?

The second issue is really a decision more for broader society. Is this something that we should be doing, something we want to be doing? This is less about the science and more about ethics and morality and legality and religious values and all sorts of other things. Reasonable people can disagree on whats appropriate and whats not appropriate.What complicates things here is that its not really an all or nothing decision. There are different scenarios where you could see parents using gene-editing on behalf of their unborn children.

I like to break it down is three scenarios. The first scenario is with parents who have medical issues that make it so that theres no way they can have natural biological children or healthy babies if they both have a bad disease and theyre going to pass it on to all of their kids unless you do something like editing. These are unusual situations, but they do exist.

The second scenario is one where parents might want to quite understandably reduce the risk of their child having some serious illness at some point in their lifetime. Im talking about things that are fairly common, like Alzheimers disease or breast cancer or heart disease or whatnot. Theres no guarantee that the editing will eliminate that risk. But you can see how parents might want to stack the odds in their kids favor. Its still medical, but its not perhaps as severe a situation with a kid whos definitely going to get the disease unless you do something.

The third scenario would be cases in which parents want to make changes that are not really medical but are more of what we would think of as enhancements. These could be cosmetic changes like hair color, eye color, things like that.

But it could potentially be much more serious things like intelligence or athletic ability or musical talent. Now, to be fair, thats theoretical. I dont think we are anywhere near knowing enough about how genes influence these things to be able to do it anytime soon. You might actually have to change hundreds of genes in order to make those changes. But you can imagine how certain parents might want to do that, might want to advance their children in the ways that they feel personally are desirable.

Bowman: Can gene editing only be performed on embryos or is it possible to edit genes in later stages of pregnancy or even post-birth?

Musunuru: Theres actually a lot of exciting work going on using gene editing to help patients, whether its adults or children. Right now its been focused mostly on adults who have terrible diseases and its really being used as a treatment to alleviate their suffering or potentially cure the diseases.

Just recently, we got the exciting news that two patients one in the U.S. and one in Europe were participating in a clinical trial. They each had a severe blood disorder. One of them had sickle cell disease. The other had a disease called beta-thalassemia. Earlier this year, they got a CRISPR-based treatment. And whats very exciting is that it looks like not only have their conditions improved significantly, it looks like they might actually be cured.

If that bears out, it would really be historic because these are diseases that affect millions of people around the world and were previously incurable. This treatment is also being explored for things ranging from cancer to liver disease to heart disease.

So theres enormous potential for benefit for living people who have serious diseases. But its a very different situation than editing embryos because youre talking about a person who is in front of you. We are trying to alleviate their suffering. That patient has the ability to freely give consent to the procedure, to weigh the benefits and risks and come up with a decision.

Bowman: How does that work? Is it some kind of cell transplant where the new cells then replicate throughout the rest of the body?

Musunuru: Yeah. It depends on the situation. I mentioned those two patients with the blood disorders. The way it worked there was the medical team used bone marrow stem cells. They basically took bone marrow as if they were going to do a transplant and then edited blood stem cells in a dish outside of the body to fix the genetic problem. And then they took those edited stem cells and put them back into the same patient. Those cells start making the blood cells that are now corrected or repaired. And by doing that, to cure the disease.

Another potential implementation is I work on heart disease. And what wed like to be able to do is turn off cholesterol genes in the liver. So what I envision is that a patient with heart disease would get a single treatment and it would deliver CRISPR into the liver and just the liver. It would turn off genes that produce cholesterol in the liver. The effect of that is permanent reduction of cholesterol levels and lifelong protection against heart disease.

This actually works really well in mice. Ive been working on this in my own laboratory for six, almost seven years now experimenting with it in monkeys. And if looks like it works and Im pretty confident that it will work we could be looking at clinical trials in a few years where were taking patients who have really bad heart disease or a very high risk for heart disease and actually giving them the single treatment within their own bodies that would turn off these cholesterol genes.

Bowman: In terms of more cosmetic applications, theres this popular idea that designer babies will be a reality at some point in the future. But how feasible would it be to use gene-editing for something very basic like choosing eye color or hair color? Are there many genes involved in determining traits like that? Are we close to being able to do that if we choose to?

Musunuru: Well, eye color, hair color, those actually turned out to be fairly simple. Theres only a small number of genes that control those. So in theory, if you wanted to do it, it wouldnt be that difficult.

Personally, my point of view is thats a trivial thing. Like why would you go through all that trouble? Do I care if your kid has blue eyes versus green eyes versus brown eyes? Maybe some parents feel that thats very important. So I think simple things like hair color, like eye color, it could be done fairly readily. I just dont see it as serious enough to warrant doing it.

The more complex things like intelligence, gosh, thats going to be so challenging. I mean, intelligence is just such a complex phenomenon. Theres some genetics involved in it, but there are so many other factors that come into that like upbringing and environment. Were not even getting close to an understanding of how someones intelligence comes about, to be perfectly honest about it.

I will point out that even though some of these things are simpler, in general, the vast majority of people are very, very uncomfortable with the idea of using gene editing of embryos for enhancements.

And I think this reflects a couple of things. I think this reflects the fact that people are more sympathetic if something like this is being used for medical purposes and much less comfortable if its being done to give a child an advantage in a way thats not medical.

It brings to mind the recent scandal where wealthy parents were trying to get their kids into good colleges by actively bribing admissions officers, faking test scores, fabricating resums. That kind of thing makes people very uncomfortable that certain people, particularly wealthy people, might try to use this technology to an extreme to advantage their children.

Theres an economic aspect to that. Wealthy parents might have better access to this technology than those who are not as wealthy. And what does that mean? If wealthy parents are somehow able to make designer babies who somehow are advantaged and other people are not, does that exacerbate socio-economic inequalities in our society?

So I think there are a few reasons why people are uncomfortable with the idea of enhancement, whereas on the whole, the majority seem to be at least somewhat open to the idea that there might be good medical uses.

Bowman: Im really happy that you brought up that socio-economic inequality aspect because I was going to ask you about that. But if we table those concerns for a moment and go way out there, theres this notion you write about that we could ultimately, theoretically, control our own evolution.

Ive heard it suggested that it could be theoretically possible to incorporate traits from other organisms that could be advantageous into our own DNA and essentially enter a new post-human stage of evolution. Is that total science fiction or do you think were entering a period where that is increasingly possible?

Musunuru:Well, with the way things are going with this technology. I mean, weve taken a step towards that. But there are many, many, many, many steps that would need to be taken to actually get to that point. But I think youre right. You see the path. We have the technology. Then its a question of perfecting the technology. A question of learning more about what genes from other species might be advantageous.

The cats out of the bag. The technology is here. Whether its five years from now or 10 years from now or 50 years from now or 100 years from now, these sorts of things will inevitably start to happen. And Im not sure theres much that those who would like to not see that happen will be able to do to stop it in the long run.

China Jails Scientist Who Gene-Edited Babies

See the original post here:
Controlling Our Own Evolution: What is the Future of Gene-Editing? - The Globe Post

Recommendation and review posted by Bethany Smith

Katherine Streeter for NPR

Katherine Streeter for NPR

Sarah Edrie says she was about 33 when she started to occasionally get a sudden, hot, prickly feeling that radiated into her neck and face, leaving her flushed and breathless. "Sometimes I would sweat. And my heart would race," she says. The sensations subsided in a few moments and seemed to meet the criteria for a panic attack. But Edrie, who has no personal or family history of anxiety, was baffled.

She told her doctor and her gynecologist about the episodes, along with a few other health concerns she was starting to notice: Her menstrual cycle was becoming irregular, she had trouble falling asleep and staying asleep, and she was getting night sweats. Their response: a shrug.

It wasn't until Edrie went to a fertility clinic at age 39 because she and her partner were having trouble conceiving that she got answers. "They were like, 'Oh, those are hot flashes. It's because you're in perimenopause,' " she says.

If you haven't heard the term "perimenopause," you're not alone. Often when women talk about going through menopause, what they're really talking about is perimenopause, a transitional stage during which the body is preparing to stop ovulating, says Dr. Jennifer Payne, who directs the Women's Mood Disorders Center at Johns Hopkins University.

"Technically, menopause is only one day in a woman's life, which is exactly when she has not had a period for 12 months," she says. "It's the period of time leading up to menopause that causes all the trouble."

And it can start earlier than you might think. Many listeners wrote to us in response to our call-out for individual experiences with menopause to say that they struggled to get medical support for perimenopause in their mid-30s and early 40s.

When Edrie went back to her OB/GYN with the fertility clinic's conclusion, she says the doctor shrugged again and told her that menopause is a normal part of life. She wasn't satisfied with that answer. "Yeah, it's a normal part of life, but it would be great if we could talk about it and figure out strategies."

With that spirit in mind, we reached out to endocrinologists, gynecologists and psychiatrists for advice about navigating this major life transition.

How early can perimenopause start?

It's quite possible for women to start to notice things changing in their mid-30s. Most women arrive at menopause between the ages of 45 and 55, but perimenopause can start as much as a decade beforehand. And about 1% of women in the U.S. reach menopause at age 40 or younger.

How do you know if you're starting perimenopause?

The most telling symptom is changes in your menstrual cycle, says psychiatrist Hadine Joffe, the executive director of the Connors Center for Women's Health and Gender Biology at the Brigham and Women's Hospital in Boston.

"It's the menstrual cycle pattern that really defines this lead-up to menopause," she says. During perimenopause, periods "might be shorter, then a long one, or then a skipped one, or then the flow might be different," says Joffe.

There's no blood or hormone test that can "diagnose" perimenopause. Joffe says a hormone test isn't helpful because hormonal cycles become erratic and unpredictable during this stage.

"There's not really one point in time when a hormone test is done that can be definitive," she says. Even if you took several tests over time, "you might get a very different readout."

Surprisingly, sometimes doctors aren't prepared to help women recognize the start of this life phase. Edrie was upset at her doctors' responses or lack thereof. "I felt so disappointed in the medical industry. How many women has my OB/GYN seen and not recognized the symptoms of perimenopause?"

What symptoms to expect

Be prepared for your PMS symptoms to possibly shift, becoming either more or less extreme, says Dr. Cynthia Stuenkel, a founding member of the North American Menopause Society and a professor and endocrinologist at the University of California, San Diego, School of Medicine. "Women might not get the same kind of breast tenderness or mood shifts that they may have noted in the past," she says.

Mood problems like depression can spike during perimenopause, especially among women who have previously experienced them. Many of our listeners wrote in to say that during perimenopause, they felt incredibly irritable and quick to anger in a way that they had never experienced before.

And of course, many but not all women experience hot flashes, though they may not recognize them. "It's hard, because no one sits us down and teaches us, 'Here's what a hot flash feels like,' " Stuenkel says. "I've seen women who think they're having panic attacks, or heart palpitations. That can be frightening."

Other common symptoms include more frequent urinary tract infections, difficulty sleeping through the night, vaginal dryness that can make sex painful, night sweats and a decrease in libido.

What treatments are there for symptoms?

Some symptoms, like heavy or irregular periods, can be managed with an oral contraceptive, which can "shut down the body's own erratic hormonal fluctuations," says Stuenkel.

"This can kind of be a lifesaver," she says. Such medication may help with hot flashes, too.

In some cases, doctors may prescribe menopausal hormone therapy, or very low doses of hormones to supplement estrogen levels. Stuenkel says it's not a fit for everyone, but it doesn't deserve the bad reputation it has in some circles. She says there was an "exodus" from the use of hormone replacement therapy after the Women's Health Initiative trial halted a study over safety concerns in 2002. But many clinicians now feel much more comfortable using hormone therapy again and usually recommend low doses, selectively, for shorter periods of time.

For people who cannot take estrogen therapy, or choose not to, Stuenkel says some drugs in the antidepressant family, such as SSRIs and SNRIs, can help with hot flashes. Stuenkel says, "While they're not perfect, they can take the edge off and help enough so that women can get a better night's sleep."

There are an abundance of nonhormonal, nondrug treatment options for managing symptoms, some of which have significantly more evidence backing them than others. In 2015, a North American Menopause Society panel found that cognitive behavioral therapy and hypnosis were significantly effective in treating hot flashes. The same panel also found that popular herbal remedies (like black cohosh, dong quai and evening primrose) are "unlikely to help," although some NPR listeners who wrote in said they got relief from some of those treatments.

For depressive and anxiety symptoms, women may want to seek out professional counseling or a psychiatrist.

When do I need to see a doctor?

You might not need to at all. Some people sail right through menopause with little trouble. But if you are experiencing symptoms that are interfering with your life, it's worth making an appointment. Some of these symptoms could indicate other problems that need treatment, such as fibroids or even cancer.

Ways to cope with symptoms

For people approaching this stage of life or who are already going through it, here are four steps for making this transition more manageable.

1. Get educated

"Information is key," says Joffe. She suggests that people approaching perimenopause age empower themselves with knowledge.

The Massachusetts General Hospital Blum Center has a curated list of suggested books. The National Women's Health Information Center has a section on menopause and perimenopause. The American College of Obstetricians and Gynecologists also has a perimenopause FAQ.

2. Monitor your health

Joffe encourages people to track symptoms: "menstrual patterns, hot flash patterns, mood issues, major life triggers." Using a paper calendar or an app to monitor symptoms can make it easier to give your doctor details that can be otherwise hard to remember.

"Knowing that information, somebody can say, 'Well, over the last six months, I only had two periods or I had hot flashes almost every day,' " Joffe says, "or, 'My mood was as bad as it gets for only two days or for a third of the time.' "

And if you bring a thorough health history to your physician and they still give you a shrug, consider a specialist. "There are OB/GYNs that specialize in perimenopause and menopause," Joffe says.

3. Practice smart self-care

Joffe encourages women to protect themselves from things that might worsen their mood or well-being. This includes reducing stress when they can and making sure they get enough sleep.

"Sleep is critical," she says. "Getting a good night's sleep, and making sure it's not broken in the middle of the night."

There are lots of online tools and apps to help with sleep, she adds.

And familiar health advice like getting enough exercise, eating well and moderating alcohol consumption apply to perimenopause too, says Dr. Steven Goldstein who is the co-author of Could It Be ... Perimenopause? and a professor of obstetrics and gynecology at the New York University School of Medicine.

At her doctor's suggestion, Edrie developed a mindfulness practice. She says, "I thought it sounded a little 'woo-woo' at first, but being able to pay attention to what my body is doing and why helps me separate those symptoms from what I need to get through my day. So I'm not overwhelmed by what my body is putting me through."

4. Cultivate community

Most of the women who wrote to NPR about their experiences going through perimenopause said that they felt alone and isolated during this transition.

Having a community to talk to can make it easier to cope with the changes, says Payne, who's going through perimenopause herself. She says she has found support from a few close friends from college.

"To be able to reach out to a group of women who are our same age and say, 'Did you go through this? And, you know, it does provide support. I think that's another version of a coping skill," she says.

Edrie says she joined a few Facebook groups dedicated to perimenopause and found one in particular where she got tips on coping with one of her most troublesome symptoms: brain fog. The conversations made her feel understood and validated.

"I can post about it in this group, and, you know, 10 women will be like, 'Oh, last week, that totally happened to me,' or like, 'I forgot my kid's computer on the top of my car and drove away,' " she says.

She says that being able to commiserate helps her get through symptoms "that maybe don't have a magic pill." Some of her online friendships have even taken shape offline. Edrie has met up with some of the Facebook group members while touring the country with her band.

Now she's a big proponent of finding community and speaking out. "As we get older, we get more and more quiet about what's going on with our bodies and ourselves and our lives. We kind of just, buck up and deal with it."

"And I feel like if we talked more about the things that are happening to our bodies even if we can't actually do anything about some of these things it would just be better for society in general if we were more vocal about it."

Read the original here:
What Is Perimenopause And How Young Can It Start? : Shots - Health News - NPR

Recommendation and review posted by Bethany Smith

Jazz Jennings of TLCs I Am Jazz has had a long road to self-confidence. The trans rights advocate began hormone blockers under a physicians supervision when she was just a child, and the trans teen has been open with followers and viewers ever since about her journey to gender confirmation surgery.

Along the way, the 19-year-old activist has struggled with her mental and physical health, as well as three complicated surgeries. But recently, the I Am Jazz star showed off her scars from bottom surgery in a poignant Instagram post about her transition and body positivity.

On Jan. 3, Jennings posted two photos of herself in a bathing suit on the beach with visible scars on her legs. She added the snapshots to both Instagram and Twitter.

These are my scars on full display in #2019, the I Am Jazz star and LGBT rights activist wrote in her caption. Im proud of my scars and love my body just the way it is. I call them my battle wounds because they signify the strength and perseverance it took to finally complete my transition.

Her family, who has always strongly supported her throughout her journey to personal and public acceptance, immediately jumped in to offer their support. Your strength is changing the world and makes me so proud to be your brother, wrote Jennings older brother, Sander Jennings, on Twitter. Thank you for inspiring me everyday.

No one has been more supportive and protective of Jennings than her mom, Jeanette Jennings, who commented under the post on Instagram: My sweet girl, you are the strongest and bravest of all the souls Ive even known and Im blessed to be your mom. Your scars are just as beautiful as the rest of you. I love you with all that I am. You make me proud everyday.

Of course, Jennings family members and loved ones werent the only ones to praise the advocate for bravely sharing her story. Instagram commenters flooded her post with gratitude and support.

Proud of you, Jazz! Scars are a sign of courage and strength, wrote one Instagram user. Youve earned them twice over.

Another supporter added, Youre really really strong Jazz, stronger than I ever will be.

One parent thanked Jennings for being so open about her struggles and triumphs alike. I know we are all strong in our own ways, but I hope my little girl is strong and brave as you when she grows up, she wrote. Wear those scars with pride, we all have some scars to deal with.

Although it looks like Jennings gender confirmation surgery might now be behind her, the upcoming season of I Am Jazz will feature her third harrowing surgery after complications from the two previous ones required her to get yet another intense procedure.

I Am Jazz Season 6 premieres on TLC on Jan. 23. In addition to deciding on a future college, planning a drag show fundraiser to support her friends gender confirmation surgery, and wrestling with the aftermath of her breakup from ex-boyfriend Ahmir, viewers will watch Jennings return to the hospital herself. It looks like the long road of Jennings transition may finally be coming to an endbut not with difficulties and challenges along the way.

Read the original:
'I Am Jazz': Jazz Shows Off Her 'Battle Scars' in Bathing Suit Photos - Showbiz Cheat Sheet

Recommendation and review posted by Bethany Smith

The thyroid plays a huge role in the body. Its a part of the endocrine system whose core function is to help your bodys metabolic hormone stay in line at all times. Problems associated with the thyroid are very common, especially in women. According to a survey by the U.S Department of Health and Human Services, one in every eight women is likely to develop a thyroid problem in her lifetime.

Since there are so many factors that may contribute to a thyroid problem, here are nine signs that may indicate that someone has a thyroid problem.

Constant fatigueA core function of your thyroid is to help metabolism. When theres an issue with metabolism control, the body is bound to feel sluggish. A constant state of tiredness and diminishing energy can be one of the most apparent indicators of a problem with the thyroid.

Weight loss or weight gainRapid weight loss when you are not actively trying to lose weight or rapid weight gain without any change in activity or diet may be a tell. The absence of a functioning thyroid slows down the bodys metabolism, and consequently, a reduction in the rate the body expends energy.

Night sweatsIf youre waking up at night with chills and soaked sheets, its time to see the doctor.

A rapid change in appetiteSince there is a problem with the thyroid, you may feel less enthusiastic about eating as each day passes. This often comes with rapid weight loss or, in some cases, weight gain.

Your cycle changesIf you start experiencing irregular periods in conjunction with other symptoms, it might be a function of your thyroid malfunctioning.

Changes in bowel movementsConstant constipation or, in some cases, severe diarrhea can result from thyroid issues.

Constant Mood ShiftsA general hormone imbalance could occasionally change moods. The same can be said where there is a thyroid problem.

While this list is not exhaustive, some of these symptoms may be common indicators for other health problems along with thyroid issues. You must consult your physician if you have any of these symptoms in conjunction with each other for a prolonged period of time.

Read more:
7 Signs You Might Have a Thyroid Problem - YouBeauty

Recommendation and review posted by Bethany Smith

UC partnerships with faith-based health systems such as Dignity Health, Catholic Health Initiatives undermines the quality of patient care in our hospitals.

It is not news to anyone that our current healthcare system struggles to meet the needs of millions of patients in California and across the country. This care gap is especially wide for brown, black, poor and queer communities that have been consistently excluded from accessing the same resources that others are given freely.

It is because of these inequities that I find it especially alarming that the UC currently has existing contracts with Dignity Health, despite the massive outpouring of opposition to affiliations with Dignity by students, physicians and Californians across the state earlier this year. UC contracts with faith-based health systems represent a blatant disregard for the UCs own stated mission of public service and undermines patient autonomy in healthcare decision making.

UC affiliation with faith-based health systems such as Dignity and CHI will severely restrict the scope and quality of health care that providers can offer, even when a patients life is threatened. According to the Ethical and Religious Directives for Catholic Health Care Services (ERDs), physicians in Catholic hospitals are barred from providing basic reproductive health care services such as contraception, abortion and in vitro fertilization. It also prohibits the provision of gender-affirming services such as hormone therapy, hysterectomies and mastectomies. These types of sweeping and biased care restrictions are immoral in any scenario and unacceptable in the setting of a publicly-funded institution.

In particular, limiting access to reproductive and gender-affirming health care can be life-threatening. Research consistently indicates that nearly every restriction on abortion access yields a corresponding rise in injury and death as a result of people attempting to self-abort. When folks are not allowed to access gender-affirming care, it undermines their right to self-determination, exacerbates mental health conditions and increases their risk of experiencing violence.

As a life-long resident of California and a future physician, I am ashamed that the UC system, an institution intended to represent the strength and future of our state, is taking a step back from its progressive vision by allowing religious institutions to restrict the quality of medical care that patients receive in our hospitals. As a student, I am outraged that the UC would detract from the quality of my medical training by agreeing to offer fewer services when it has the resources to provide more.

Patients deserve nothing less than wholly inclusive, evidence-based care that addresses every aspect of their health.I urge UC leadership to reject the influence of religious institutions on our healthcare system and instead consider the many opportunities available to increase patient access to high-quality, comprehensive health care services.

Written by: Caitlin Esparza

Caitlin Esparza is a second-year medical student and co-president of Medical Students for Choice at UC Davis.

To submit a guest opinion, please email opinion@theaggie.org

Read more:
Religious initiatives have no place in the UC health care system - The Aggie

Recommendation and review posted by Bethany Smith

The direct to consumer testing market comes in many flavors these days, with companies like 23andMe dominating headlines with their genetic/ancestry tests targeting folks eager to learn more about themselves. Also joining the fray are tests designed to help women in theory, at least assess fertility by counting the number of eggs left in their ovaries.

Sounds like a great idea. Just one problem: egg counts may not be such a great indicator of fertility, according to the American College of Obstetricians and Gynecologists.

Still, that doesnt mean these tests have no value. A new study suggests they can empower women. And thats especially true for those who do not fit into the binary gender categories that health insurers may require for covering clinical versions of the test that cost ten times as much.

At-home tests for reproductive health for women have been around since the first home pregnancy kits hit the market in 1978. In 1989 came the first DIY ovulation predictor kits.

Tests to measure ovarian reserve how many eggs are left dont have the track record of these older tests. And they may not even be accurate for women who havent had difficulty conceiving or are taking birth control pills.

But do they still have value?

Moira A. Kyweluk, a fellow in the department of Medical Ethics and Health Policy at the Perelman School of Medicine at the University of Pennsylvania, decided to find out. She interviewed 21 women, of diverse backgrounds and circumstances, to tap their thoughts about direct-to-consumer (DTC) testing of ovarian reserve.

The women were recruited from social media, community center notice boards, and listservs, in Chicago during the first half of 2018. The findings appear in Social Science & Medicine.

Egg counters sold to consumers are part of the FemTech market. I view DTC testing as an entry point into what I term the new (in)fertility pipeline for women today. Because it is low cost and widely available, its reaching a larger demographic, people of diverse identities and backgrounds, and raising awareness of more advanced procedures and technologies like egg freezing, Dr. Kyweluk said in a news release.

But she questions the accuracy of these tests. Consumers continue to desire these tests, and theyre attractive, but they dont deliver on their promise.

The number of immature eggs in the two ovaries dwindles as a female ages.

Seven to eight million tiny undeveloped eggs are already present in a 20-week female fetus. That means, curiously, that a pregnant woman houses the cells that, when fertilized, will become her grandchild.

By birth, about a million oocytes remain, and that number is halved by puberty. Then by the start of menopause, around age 51, only 1,000 or so eggs remain. Over her lifetime, a woman ovulates 300 to 400 eggs.

Each egg occupies a chamber called a follicle. Each month between puberty and menopause, the largest egg pops out in response to a crescendo of luteinizing hormone thats ovulation. Meanwhile, anti-Mllerian hormone (AMH) suppresses release of the other, smaller eggs.

Its seemingly simple: The more AMH, the more eggs are left.

Measuring AMH is the basis of clinical tests used to predict ovulation in women undergoing in vitro fertilization (IVF) or egg freezing, presumably because theyve been unable to conceive. But the accuracy of AMH level to predict ovarian reserve among women who are fertile isnt known.

And so in 2019, the American College of Obstetricians and Gynecologists (ACOG) issued a statementthat consumer kits to measure AMH arent ready for prime time. The products are too variable and not standardized.

Serum anti-Mllerian hormone level assessment generally should not be ordered or used to counsel women who are not infertile about their reproductive status and future fertility potential, according to the statement. It includes a hypothetical case that illustrates misinformation about AMH testing:

A 26-year-old woman comes in for a wellness exam and the provider mentions the effects of aging on fertility. Im not ready to become pregnant now, but I would in the future. My friend recently took a blood test to check her egg count, so she knows how much longer she can wait to have a baby. Can I have that test?

If she meets criteria for infertility, her insurance might fork over a large part of the $1,500 cost for such a test. Thats why a DTC test kit that requires a pinprick of blood and costs $79 to $199, without requiring evidence of anything or an uncomfortable meeting with a health care provider, is an attractive alternative if it provides useful information.

The website for an ovarian reserve test kit from Modern Fertilitydoes comport with the ACOG statement.

Want kids one day? the opening page announces, like asking if you want to order a pizza. Women are invited to join a weekly egginar for information before they dive into the science that helps you do you.

Clicking ahead shows clear warnings that the test wont reveal infertility, but will indicate if a womans egg count is more or less than is average for her age. It sounds like peering into an egg carton to count whether it has all 12 expected eggs.

The test measures AMH, FSH (follicle stimulating hormone), and E2 (estradiol). Thats important to know, because a search for ovarian reserve testing on Amazon yielded first theEverlyWell ovarian reserve test egg quantity indicator, which measures only FSH not the important and telltale AMH.

The Modern Fertility test is also quite clear about what it can and cant do. A woman can discuss the results with her physician and ask about further testing and possibly pursuing IVF or egg freezing. Or, if she only has half a dozen in the egg carton analogy, she might expect to experience menopause sooner than shed thought.

Countering the ACOG statement is the LetsGetChecked product. The Ovarian Reserve Test is for anyone who is curious about their fertility status, according to the website. It costs $139.

The website for LetsGetChecked has a helpful list of conditions that can accelerate the whittling down of egg number, which a consumer can bring to a physician to explore further. These include polycystic ovary syndrome, chromosomal abnormalities such as Turners (XO) syndrome and fragile X, endometriosis, ovarian tumors, autoimmune disorders, and pelvic injuries. The woman would already know if shed had chemotherapy or radiation, which can damage eggs.

Dr. Kyweluk designed a study that would take a real-world view of the issues that might prompt a woman to take a DTC ovarian reserve test. Her paper is a series of vignettes.

The research differs from standard medical studies in that it is ethnographic, taking into account race and ethnicity, relationship status, insurance, sexual orientation, and socioeconomic group, because the reasons for seeking ovarian reserve testing go beyond biology. Dr. Kyweluk interviewed the women as they were deciding whether or not to take a test. She had a grant that paid for those who wanted to go ahead, using one company that provided access to a nurse practitioner to interpret findings.

Of the 21 participants, aged 21 to 45, 14 were white, 14 heterosexual, and 7 bisexual or queer. Three different scenarios of women seeking the DTC test indicate the variability of need.

Yvette was a 37-year-old African-American who had been trying with her husband to conceive for a decade. Their health insurance was quick to cover birth control, but assessing fertility, not so much.

When Yvettes ovarian reserve results were normal, the nurse suggested an ovulation predictor to better time intercourse and have her husband have a semen analysis.

Naomi was typical of a high-income, highly-educated white woman, who was stressing over whether she really wanted to have a baby. Would an ovarian reserve test indicate that it wasnt in the cards? Then she could stop thinking about it, or freeze eggs, which she could afford to do. Many women cant.

Josephine was 35 and African-American. A devout Catholic, she had just ended a long-term relationship. Her faith prompted her to ask, was I meant to be a parent? and she felt that the ovarian reserve test, if she had too few eggs, might reveal no.

Several women reported that taking the ovarian reserve test empowered them. Caroline, for example, was a 30-year-old queer white woman with a female partner. Medicaid had denied them coverage of any elective tests, and they didnt meet the diagnostic criteria for infertility because they were not a heterosexual couple.

The DTC test made me feel Im in control, like I can want some information, pay for it, and then get it. I didnt have to rely on a doctor to decide it was necessary for me to know this information. This is information that Ive wanted forever, Caroline told the researcher.

In one confusing case, the cisgender female partner (Breanne) of a transgender man (Tal) discovered, using a DTC test, that her ovarian reserve was quite low, something shed suspected from her age and irregular menstrual periods. The couple had planned to use a sperm donor and Breanne would carry the pregnancy. But if Breanne didnt have enough eggs, what would they do?

They had an idea. Did Tal still make eggs?

Hed been receiving testosterone injections for a decade as part of gender-affirming treatment and sported a full beard. But the DTC ovarian reserve test revealed he was still making the normal number of eggs for a cisgender woman his age. Hed carry the pregnancy!

But when Tal went to a clinical lab to repeat the ovarian reserve testing, the medical staff continually misunderstood their situation. Ultimately, Tal felt that inexpensive ovarian reserve testing was simply a foot in the door to other, more costly procedures, Dr. Kyweluk writes.

The bottom line: A DTC ovarian reserve test can give a woman a sense of control, but at the expense of an incomplete, confusing, or even meaningless clinical picture.

From a broader perspective, is egg counting an example of the medicalization of the range that is normal reproductive biology? Will it create the patients-in-waiting scenario that describes newborn screening that identifies genetic diseases well before they cause symptoms?

Steve Jobs is famous for inventing things that we didnt know we needed the iPod and then the iPhone. To paraphrase and take him a bit out of context, A lot of times, people dont know what they want until you show it to them.

Just as it took years for so many of us to realize that we couldnt live without smartphones, it will take time for data to accrue that improve the accuracy of DTC ovarian reserve tests in predicting infertility. Until then, it might be just one more thing to worry about.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

Read the rest here:
How fertile are you? 'Ovarian reserve' DTC tests that count your eggs offer mixture of control and misinformation - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

By far, the most popular forms of intermittent fasting are the 18:6, 16:8, and 14:10 time-restricted eatingplans, in which you abstain from food for 18, 16, and 14 hours per day, respectively. While breaking these types of fasts doesn't require quite as much planning as breaking an extended fast, there are still some general recommendations.

First and foremost, stick to whole foods and opt for a mix of macronutrients when you break a fastyou don't want a straight shot of carbohydrates (especially refined carbs) on an empty stomach.

"Definitely avoid carb-loaded meals and sugary drinks as they will cause a blood sugar roller coaster, raising your insulin levels and making you feel even more hungry," says Amy Shah, M.D., who uses intermittent fasting in her practice. "Additionally, having lots of sugar will make fasting for the next day even harder because your hunger hormones [like ghrelin] will be raised."

So what should you eat?"For a standard 16:8 plan, one could break a fast with a low-glycemic meal of choice," says Ali Miller R.D., L.D., CDE, registered dietitian and functional medicine practitioner. "If you're going to have carbs, ensure that they're balanced with protein and fat. A salad with protein, eggs with avocado and vegetables, a homemade protein shake, or a leftover protein and roasted veggies could all work as meal number one."

Portion size matters a bitparticularly when you get into the more intense time-restricted eating plans like 18:6 or 20:4. Even though you may be quite hungry when breaking your fast, particularly if you're new to IF, avoid eating a huge meal or you might overload your digestive system and experience symptoms like bloating. Typically, "hefty snack or small meal is best," says Miller.

Some specific foods you can mix and match to incorporate into your first post-fast meal include:

Read more:
Intermittent Fasting? Here's The Right Way To Break Your Fast - mindbodygreen.com

Recommendation and review posted by Bethany Smith

About half of all Americans are trying to lose weight, and with the weight loss service industry being worth billions of dollars some estimates put it at over seventybillion dollars there are a lot of hucksters and well-intentioned-yet-misinformed people trying to cash in.

There are a lot, a lot, a lot of myths out there about the best way to lose weight and about nutrition in general: which macronutrients are worse (is it fat this year, or carbs?) and whether you can supercharge your liver with a detox tea. Trainer and big-time-Instagram-guy Jordan Syattsat down with us to run over the worst myths in nutrition that need to die. Lets get started.

Editors note: The content on BarBend is meant to be informative in nature, but it shouldnt take the place of advice and/or supervision from a medical professional. The opinions and articles on this site are not intended for use as diagnosis, prevention, and/or treatment of health problems. Speak with your physician if you have any concerns.

You dont need to count your calories if you want to lose weight, says Syatt. But regardless of whether or not youre counting calories, your calories always count.

No matter what, your body obeys the laws of thermodynamics and it runs on energy. Energy comes into the body by way of food and is often stored in the form of fat or carbohydrates (glycogen).

There are a lot of ways to control your calorie intake: maybe increase your fiber, increase your protein, lower your fat intake, all of these can work without an individual counting their calories. But they work because they (can) lead you to consumer fewer calories, which is what controls your waistline.

It doesnt matter if you dont look at your bank account, says Syatt. If youre spending all the money, its gonna drain.If youre putting a bunch of money in, youre going to save it up, regardless of whether or not youre tracking it. This is whats really important to remember about calories.

The composition of calories changes, of course. If youre comparing a 500-calorie salad with a 500-calorie cheeseburger, the salad probably has more fiber, vitamins, and minerals, its probably more filling, and all of this can contribute to better health and weight management. Just remember that even healthy foods contain calories.

[Related: Check out our podcast with Jordan Syatt]

Yes, your body weight is a matter of energy balance. If you are in a calorie deficit you will lose weight, in a calorie surplus youll gain weight.

But quality and quantity matter here.As mentioned above, different foods have different effects on your appetite, but its also important to note that your balance of protein, carbs, and fat will affect what kind of weight you lose or gain.

If youre doing a smart workout program, youll lose more fat and retain more muscle in a deficit and gain more muscle and less fat in a surplus if youre making sure that enough of your calories come from protein usually 0.6 to 1 gram of protein per pound of bodyweight is recommended.(1)

Furthermore even if you hit the precise macro balanceyoure aiming for to but youre eating most of your calories from junk food and youre not eating fruits and vegetables, youll run low on important nutrients like magnesium, zinc, B-vitamins, and plenty of others. If youre low on these nutrients (or others) then performance in the gym can suffer, sleep can suffer, inflammation can increase, recovery can be impeded, focus takes a dive, immunity is compromised the list goes on. (And on.) All of these can negatively impact your physique.

Quality and quantity matter when it comes to nutrition, dont let anyone tell you otherwise. You can find room for junk food in your calories and still lose fat or gain muscle, but be mindful of your nutrients, macro and micro.

[Related: The Right Macros for Fat Loss vs Muscle Gain]

When people do keto they tend to lose weight faster, especially initially, because nearly eliminating carbohydrates causes the body to lose a lot of water weight, says Syatt. So they see very radical weight loss at the beginning, but then thats why they have a plateau almost equally as quickly a few weeks later. Because theyre not just losing water weight, they have to lose fat now.

The reality is that if youre not in a calorie deficit, you wont lose fat. Many keto proponents claim that keto causes the body to burn more fat for fuel, and while this may be true, this doesnt seem to promote more weight loss when calories are controlled, according to ameta-analysis of thirty-two trials that compared carbohydrate intake.(2)

The reality is you can do keto and see great progress, or you can not do keto and see great progress, says Syatt. As long as your calories are in check, youre going to lose fat over time.

For those who arent controlling calories, there is some evidence that keto can potentially be useful for managing hunger, which would result in weight loss. But again, thats because there are fewer calories being consumed, not because keto is anything magical in that regard. And importantly, whether or not keto works or feels good or results in fewer calories being consumed really depends on the individual.

This is a little related to keto, but irrespective of fat intake, many try to limit carbohydrates in general (bunless burgers, riceless burritos, etc.) because of a fear that carbs lead to fat gain.

Now, if youre cutting carbs and not replacing them with anything else, then youll be consuming fewer calories and thatll lead to weight loss, all else being equal. But for many people, dropping carbs means dropping fiber (perhaps the best natural appetite suppressant there is) and they can wind up eating more calories as a result.

Plus, carbs are often great sources of nutrients! Fiber, again, is great, with links not only to weight loss but also to lower risks of bowel cancer, Alzheimers disease, and more.(3)(4) But legumes, whole grains, and fruit are also jam packed with vitamins, minerals, phytonutrients, and antioxidants that may lower the risk of practically every disease there is. So there are plenty of reasons to limit refinedcarbs like sugar and white flour theyre not filling and very low in fiber and nutrients butits really important not to throw the baby out with the bathwater when it comes to carbohydrates.

This idea that fat makes you fat is bullshit, says Syatt. And we know it because there are many people eating very high fat diets, like the ketogenic diet, and losing fat. If fat made you fat then anyone doing keto would immediately be obese. Im not against keto, Im just forwhatever works for you.

Keto isnt inherently bad for you. Carbs arent inherently bad for you. Fat doesnt make you fat. Eating too many calories makes you fat, end of story.

There is a little caveat here: fat has more than twice the calories of protein or carbs, with nine calories per gram versus four calories per gram. So ten grams of fat will make you fatter than ten grams of chicken breast, if youre already eating over your daily calorie burn.

But that doesnt mean you should eliminate fat: it serves really essential functions like maintaining hormonal health and improving your absorption of important nutrients, like Vitamin D. If you have a diet without any fat at all, you wont last long, and if you have a diet thats deliberately, extremely low in fat, then important hormones like testosterone will take a hit.

[Related: The Best Natural Ways to Increase Testosterone]

Youre looking for a shortcut? You got it! Just grab a fat burner and your six pack will be waiting for you at the end of the bottle.

Were kidding. Thats not how they work.

Its not that fat burners are ineffective, exactly. There are some studies that have found that cayenne pepper, for instance, which is in just about every fat loss product out there, does increase the amount of calories you burn. But a lot of studies put it in the area of 5 to 10 calories, and some research shows no effect at all.(5)(6)(7)(8)

Some studies put it higher, at 50 calories, but thats still just half a tablespoon of peanut butter not actually that much in the grand scheme of things.(9)

Now for some people, that still matters a lot. Lets say youre a bodybuilder, you need to have 1,900 calories, but you just cannot have less than 2,000 calories without feeling extremely deprived. Popping a fat burner might be useful in that instance, as there are plenty of fat burners that probably burn around one to two hundred calories.

But you have to remember:

The reality is if your training isnt in check and your nutrition isnt in check and your sleep isnt in check, you have no reason to buy fat burners, says Syatt.

Do detoxes cleanse your system and wash out all the dirty toxins you have?

The reality is this: detoxes and cleanses dont do anything for you, says Syatt. Theres zero research to support it whatsoever.A very simple question to ask people trying to sell you detoxes and cleanses is which toxins are these cleaning out, specifically? Theyre always at a loss for words.

When people claim detoxes are scientifically backed, its usually because

Some studies have found that people who are hospitalized with liver issues might experience a slight improvement in some symptoms in conjunction with other treatment methods when theyre supplementing with a little milk thistle.(10) Marketers will see studies like that, conclude that milk thistle helps your liver work, your liver helps you filter waste, therefore milk thistle detoxes you. Theres no evidence for this for people with a healthy liver.

If your liver isnt functioning properly, you should see a fucking doctor! says Syatt. Not a fake a detox tea from someone selling diarrhea nonsense on Instagram. Dont trust the influencer, go to a doctor if your liver isnt working properly.

Theres no good evidence for this. Some older studies from the 1980s found that eating more protein resulted in more waste filtration from the kidneys, so they thought the kidneys were undergoing unnecessary stress.(11) But later studies found that wasnt the case for healthy kidneys, and some research has even looked specifically atathletes consuming well over a gram of protein per pound of bodyweight, and didnt find signs of kidney issues.(12)(13)(14)(15)

Sometimes, people with kidney problems are often advised to go on low protein diets, yes.(16) But people with broken legs are also advised not to run marathons. If youre healthy then evidence suggests high protein diets are fine.

[Related: Our full article on protein intake and kidney function]

Fortunately, this isnt true.

I love eating before bed, I eat a lot of food at night, and one of the easiest ways to dispel this myth is to look at all the research surrounding intermittent fasting, says Syatt. People basically save the vast majority of their calories before they go to bed, and what weve consistently found and it sounds boring and obnoxious, but its true as long as youre in a calorie deficit, youll lose fat.

Thats the reality.A calorie is a calorie at 8am and 8pm, it doesnt matter what time youre eating, it matters how much youre eating. Thats it.

If you read muscle mags in the 90s, theres a good chance you heard that eating six small meals a day boosts your metabolism and makes you burn more fat. Or conversely, that not eating frequently say, skipping breakfast causes you to gain fat.

Not true. Skipping a meal or two isnt going to slow down your metabolism or cause you to burn less fat.

A lot of people will tell you that because fasting increases the amount of growth hormone in the body, fasting helps you to build muscle. Its true that fasting has been seen to up your growth hormone, but this hormone really is more about preserving muscle it means that if you skip a meal or two, your body wont start eating all its muscle in some kind of starvation mode.(17)(18)(19) You can eat when you want. If youprefersix meals a day, thats fine. If youd rather save your calories for the end of the day, it doesnt look like itll make much of a difference.

OK, maybe if youre trying to win the Mr. Olympia competition, youd rather have ten meals to keep muscle protein synthesis as consistent as possible. But for the average person, even the one with a six pack, meal timing has no real, practical benefit. A 2016 study had a great example:when comparing people trying to lose weight over a period of eight weeks, people eating every day lost as much weight as people eating everyotherday when the calories were the same.(20)

If fasting helps you control your calories better, or ifnotfasting helps you control your calories better, then do what works for you! Neither is really that superior; it comes down to individual preference.

I think its a really important thing for people to take home, says Syatt. Were not saying that fasting is better for you or worse for you, were saying that whatever you choose to do fasting, keto, Paleo, Weight Watchers, whatever it is do what you enjoy and what you can do consistently.And if someones trying to sell you something and shove one method down your throat and say everything else doesnt work, dont listen to them.Because what were trying to say is that everything works, as long as you can do it consistently and your calories are in check.

1.Rodriguez NR, et al. Position of the American Dietetic Association, Dietitians of Canada, and the American College of Sports Medicine: Nutrition and athletic performance. J Am Diet Assoc. 2009 Mar;109(3):509-27.2.Hall KD, et al. Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition. Gastroenterology. 2017 May;152(7):1718-1727.e3.3.Aune D, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011 Nov 10;343:d6617.4.Cremonini AL, et al. Nutrients in the Prevention of Alzheimers Disease. Oxid Med Cell Longev. 2019 Sep 4;2019:9874159.5.Chaiyata P, et al. Effect of chili pepper (Capsicum frutescens) ingestion on plasma glucose response and metabolic rate in Thai women. J Med Assoc Thai. 2003 Sep;86(9):854-60.6.Snitker S, et al. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. Am J Clin Nutr. 2009 Jan;89(1):45-50.7.Smeets AJ, et al. The acute effects of a lunch containing capsaicin on energy and substrate utilisation, hormones, and satiety. Eur J Nutr. 2009 Jun;48(4):229-34.8.Galgani JE, et al. Effect of capsinoids on energy metabolism in human subjects. Br J Nutr. 2010 Jan;103(1):38-42.9.Galgani JE, et al. Effect of dihydrocapsiate on resting metabolic rate in humans. Am J Clin Nutr. 2010 Nov;92(5):1089-93.10.Saller R, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008 Feb;15(1):9-20.11. von Herrath D, et al. Glomerular filtration rate in response to an acute protein load. Blood Purif. 1988;6(4):264-8.12. Knight EL, et al. The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med. 2003 Mar 18;138(6):460-7.13. Beasley JM, et al. Higher biomarker-calibrated protein intake is not associated with impaired renal function in postmenopausal women. J Nutr. 2011 Aug;141(8):1502-7.14. Antonio J, et al. A High Protein Diet Has No Harmful Effects: A One-Year Crossover Study in Resistance-Trained Males. J Nutr Metab. 2016;2016:9104792.15. Poortmans JR, et al. Do regular high protein diets have potential health risks on kidney function in athletes? Int J Sport Nutr Exerc Metab. 2000 Mar;10(1):28-38.16. Levey AS, et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1996 May;27(5):652-63.17.Moller L, et al. Impact of fasting on growth hormone signaling and action in muscle and fat. J Clin Endocrinol Metab. 2009 Mar;94(3):965-72.18.Vendelbo MH, et al. Exercise and fasting activate growth hormone-dependent myocellular signal transducer and activator of transcription-5b phosphorylation and insulin-like growth factor-I messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab. 2010 Sep;95(9):E64-8.19.Lanzi R, et al. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects. Metabolism. 1999 Sep;48(9):1152-6.20.Catenacci VA, et al. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. Obesity (Silver Spring). 2016 Sep;24(9):1874-83.

Visit link:
10 Nutrition Myths That Need to Die (With Jordan Syatt) - BarBend

Recommendation and review posted by Bethany Smith

Tert-butanol Market Outlook provides thoughtful analysis of current issues facing the industry, along with current facts and statistics about the production and application in Tert-butanol Market.. The Tert-butanol market accounted for $XX million in 2018, and is expected to reach $XX million by 2024, registering a CAGR of YY% from 2019 to 2024.

The moderately consolidated market for tert-butanol has its hopes pinned on the emerging economies of Asia Pacific, Latin America, and the Middle East and Africa. These regions rake in the most revenue owing to the growing use of tert-butanol in the food and beverages, automotive, personal care products, and construction sectors and as a result, most players both established and new have turned their focus to developing countries.Read Report Details at https://www.proaxivereports.com/6598

List of key players profiled in the Tert-butanol market research report:

Merck KGaA, LyondellBasell Industries Holdings B.V., Evonik Industries AG, Kuraray Co., Ltd, Tokyo Chemical Industry Co., Ltd., Tiande Chemical Holdings Limited, Struchem Co., Ltd., Sisco Research Laboratories Pvt. Ltd., AppliChem GmbH, Alfa Aesar, TonenGeneral Sekiyu K.K., Lotte Chemical Titan Corporation, Capot Chemical Co., Ltd., Zibo Qixiang Petrochemical Industry Group, Maruzen Petrochemical, Avantor Performance Materials, Finar Limited,

By End-userPaints & Coatings, Flavors & Fragrance, Pharmaceuticals, Others,

By Product TypePharmaceutical Grade, Chemical Grade,

Request for Sample Report athttps://www.proaxivereports.com/request-sample/6598

The global Tert-butanol market is segmented based on product, end user, and region.

Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and, rest of Asia-Pacific) and EMEA (Brazil, South Africa, Saudi Arabia, UAE, rest of EMEA).

Ask more details or request custom reports to our experts athttps://www.proaxivereports.com/pre-order/6598

Moreover, other factors that contribute toward the growth of the Tert-butanol market include favorable government initiatives related to the use of Tert-butanol. On the contrary, high growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

Key Benefits for Stakeholders from Tert-butanol Market Report:

This report entails a detailed quantitative analysis along with the current global Tert-butanol market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.The Tert-butanol market size and estimations are based on a comprehensive analysis of key developments in the industry.A qualitative analysis based on innovative products facilitates strategic business planning.The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the Tert-butanol industry.

Purchase Tert-butanol Market Report athttps://www.proaxivereports.com/checkout/6598

See the original post here:
At US$ 3300 Mn Reached Male Hypogonadism Market With 3.7% CAGR Value In The Year of 2026 - Fusion Science Academy

Recommendation and review posted by Bethany Smith

The opioidepidemic imposes scrutiny on clinicians and patients alike; with particularemphasis on cancer survivors who require the drugs to manage their pain. Howdoes the clinician determine who is at risk for persistent opioid use andabuse? A group of radiation oncologists and pain specialists from theUniversity of California San Diego (UCSD) conducted a study to answer thisvital question, and presented their findings at the 2019 American Society forRadiation Oncology (ASTRO) Annual Meeting, held in Chicago.1

More than 50% of oncology patients who receive curative treatmentsuffer from moderate to severe pain that can be relieved by opioids, according toWHO pain guidelines.2 Although these medications are accepted forrelief of such acute pain, their use in situations where patients have chronicpain (lasting for more than 3 to 6 months) is not so well defined. There arerisks of such long-term administration, such as medication tolerance and lossof efficacy over time. The potential of toxicity can lead to conditions such asdepression, difficulty concentrating, and sedation, and the patient may alsodevelop hyperalgesia or hypogonadism. There are also the well-known risks ofdependence, misuse and abuse, and accidental overdose. The authors of thisstudy support adopting the clinical practice guideline of the American Societyof Clinical Oncology (ASCO) when using opioids to achieve optimal pain management,using risk mitigation strategies such as judicious opioid use, drug screening,adherence monitoring, and strategies for alternative pain management.1,3

Creating a Risk Score

The radiation oncologists sought to identify clinical risk factorsand create a risk score, utilizing an evidence-based risk stratificationapproach to identify patients who might benefit from a proactive approach bythe oncology nurse or other clinician. Their efforts resulted in the Cancer OpioidRisk Tool, a validated prediction tool forassessing the risk of persistent opioid use 1 to 2 years after treatment, estimatingrisk aslow (less than 5%), intermediate (5% to 25%) and high (greaterthan 25%).

The researchers usedthe Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI)database, which contains detailed electronic health record information on allveterans within the VA health care system. This database provided data on106,732 veteran cancer survivors whose cancer had been diagnosed between 2000and 2015.1

Common diagnosesamong the VA patients were 1 of 12 noncutaneous, nonhematologic malignancies,including cancer of the bladder, breast, colon, esophagus, head and neck,kidney, liver, lung, pancreas, prostate, rectum, or stomach. The study groupincluded patients who were treated with surgery, radiation therapy (RT), orboth and who were alive without disease recurrence 2 years after treatment hadbegun.1

Two models of the Cancer Opioid Risk Tool are available on thewebsite: Full and Lite. Using an automated algorithm, the risk for persistentopioid use is calculated based on data entered by the clinician. The lite modeluses 5 variables: age, presence of depression, alcohol abuse, prior opioid use,and whether treatment included chemotherapy. The more complex, full, model usesthese 5 variables plus employment status, psychiatric diagnoses, race, tobaccouse, body mass index (BMI) category, type of cancer, disease stage, and localtreatment. (Note, although improvements to the tool are ongoing, it istotally functional.) The full version is recommended if providers have time andaccess to all of the relevant information.

Risk Factors for Persistent Opioid Use

The radiationoncologists determined that the rates of persistent posttreatment opioid useamong the VA cohort varied by type of cancer and prior opioid use. Significantfindings included:

Risk factors firstreported in the San Diego study were younger age, white race, BMI, unemploymentat the time of cancer diagnosis, lower median income, use of chemotherapy,increased comorbidity, and tobacco use. Substantially increased odds ofpersistent opioid use were associated with patients who had a history of prioralcohol abuse, nonopioid drug abuse, chronic or intermittent opioid abuse, anddepression.1

Study limitations included whetherresearch on mostly male military veterans would translate to a civilianpopulation of both sexes. Also, veterans who saw combat were exposed to mentaland physical trauma at higher rates than the general population, and this couldincrease their risk for opioid dependence or abuse. Furthermore, thispopulation is more likely to have health insurance and are therefore lesslikely to be financially insecure than the general population.1

Managing patients at risk

The authors notethat the absolute rate of persistent opioid use, abuse, and dependence wasrelatively low among the cohort of VA cancer survivors, especially among thosewho were opioid-nave. They believe that improved risk stratification willallow for personalized risk assessment and improve the safety of painmanagement in cancer survivors. The lite model of the CancerOpioid Risk Tool was validated in an independent test cohort. A more robustvalidation of the newer full tool will require a prospective study.

Strategies thatcan help clinicians better manage patients at risk of persistent opioid use includeestablish a signed treatment agreement, utilize periodic urine drug testing,educate patients and their caregivers on the risks of abuse and/or misuse, offerreferrals to pain and palliative medicine specialists, and avoid high riskformulations while minimizing lower total daily medication doses.

References

1. Vitzthum LK, Riviere P, Sheridan P, et al. Predicting persistent opioid use, abuse and toxicity among cancer survivors [published online November 22, 2019]. J Natl Cancer Inst. doi: 10.1093/jnci/djz200

2. World Health Organization. Cancer Pain Relief : With a Guide to Opioid Availability. 2nd ed. Geneva, Switzerland; 1996. https://apps.who.int/iris/bitstream/handle/10665/37896/9241544821.pdf?sequence=1&isAllowed=y. Accessed January 13, 2020.

3. Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325-3345.

This article originally appeared on Oncology Nurse Advisor

Follow this link:
Emerging Clinical Tool Predicts Risk of Persistent Use of Opioids After Treatment in Patients With Cancer - Renal and Urology News

Recommendation and review posted by Bethany Smith

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardias large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005200/en/

"BlueRock is a leader in the field of cell therapy and our collaboration is a perfect match of mission and capabilities. This relationship allows us to utilize our experience in iPSC process development to help advance potential cell therapies for cardiac diseases," said Stefan Braam, CEO of Ncardia.

"There are hundreds of millions of people worldwide that suffer from degenerative cardiovascular disease where the root cause is the loss of healthy heart muscle cells, and where medical treatment options are limited. BlueRocks authentic cellular therapy is a novel approach that has the potential to transform the lives of patients, but will require the manufacture of our cell therapies at unprecedented scale. The Ncardia team has developed key technologies related to this scale-up challenge, and we are pleased to work with them as we advance BlueRocks novel CELL+GENE platform towards the clinic and those patients in need," said Emile Nuwaysir, President and CEO, BlueRock Therapeutics.

About BlueRock Therapeutics

BlueRock Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics CELL+GENE platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics cell differentiation technology recapitulates the cells developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRocks culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit http://www.bluerocktx.com.

About Ncardia

Ncardia believes that stem cell technology can deliver better therapies to patients faster. We bring cell manufacturing and process development expertise to cell therapy by designing and delivering human induced pluripotent stem cell (iPSC) solutions to specification. Our offerings extend from concept development to pre-clinical studies, including custom manufacturing of a range of cell types, as well as discovery services such as disease modelling, screening, and safety assays. For more information, visit http://www.ncardia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005200/en/

Contacts

BlueRock:media@bluerocktx.com

Ncardia:Steven Dublinmedia@ncardia.com

Excerpt from:
Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of...

Recommendation and review posted by Bethany Smith

Theres a team of scientists who basically discovered live robots. You read that right. They found a new purpose for living cells, which they took from frog embryos, and they constructed new life forms. These life forms were named Xenobots, and they can move in small places and carry stuff, too. They also want to try to see if they are useful in medicine.

Apparently, they can heal themselves after theyre cut, which gives them a longer life span. They are not a species of animals, and they are not robots in a real way. As Joshua Bongard states, Its a new class of artifact: a living, programmable organism. He is a computer scientist at the University of Vermont.

A supercomputer developed these live robots at UVM. The idea behind this creation is not a new one. But it is the first time they actually improved it from scratch. The team was led by doctoral student Sam Kriegman, who used an evolutionary algorithm to develop thousands of designs for these new life forms.

They gave the program the basic rules about biophysics about the frog skin and the cardiac cells. They tested about a hundred algorithms to find the best design. Then, the team worked with microsurgeons to transfer the silicon designs into life. They took the stem cells from Xenopus lavevis, an African frog. Then the embryos were assembled in body forms, so the cells began to work.

Almost everything we see today is made out of steel, silicon, or plastic. While its true that the material is durable, it also creates human health problems. Bongard stated that the living tissues degrade quickly. Also, these living robots made with frog cells could help us live a healthier life. More research will be conducted.

Tanya is an expert in reddit and health subjects. She finds good stories where no one ever thinks to look.

Continued here:
The Living Robots Made With Frog Cells Could Boost Our Health - Dual Dove

Recommendation and review posted by Bethany Smith

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request PDF Sample of Cell Separation Technology Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases.

Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Enquiry for Discount on Cell Separation Technology Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration(CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

Read the rest here:
Cell Separation Technology Market Statistics, Demand and Forecasts to 2027 Examined in New Research Report - Dagoretti News

Recommendation and review posted by Bethany Smith

US Stem Cell (OTCMKTS:USRM) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

39.7% of National Research shares are owned by institutional investors. 16.7% of US Stem Cell shares are owned by insiders. Comparatively, 4.5% of National Research shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for US Stem Cell and National Research, as provided by MarketBeat.com.

Volatility & Risk

US Stem Cell has a beta of 4.87, meaning that its stock price is 387% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Valuation and Earnings

This table compares US Stem Cell and National Researchs gross revenue, earnings per share (EPS) and valuation.

National Research has higher revenue and earnings than US Stem Cell.

Profitability

This table compares US Stem Cell and National Researchs net margins, return on equity and return on assets.

Summary

National Research beats US Stem Cell on 7 of the 9 factors compared between the two stocks.

US Stem Cell Company Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Companys portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Companys clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Go here to see the original:
National Research (NASDAQ:NRC) versus US Stem Cell (NASDAQ:USRM) Head-To-Head Review - Riverton Roll

Recommendation and review posted by Bethany Smith

There is some truth to the longstanding anecdote that your locks can lose color when youre stressed.

A team of researchers has found that in mice, stressful events trigger damage the stem cells that are responsible for producing pigment in hair. These stem cells, found near the base of each hair follicle, differentiate to form more specialized cells called melanocytes, which generate the brown, black, red and yellow hues in hair and skin. Stress makes the stem cells differentiate faster, exhausting their number and resulting in strands that are more likely to be transparent gray.

The study, published Wednesday in Nature, also found that the sympathetic nervous system, which prepares the body to respond to threats, plays an important role in the graying process.

Normally, the sympathetic nervous system is an emergency system for fight or flight, and it is supposed to be very beneficial or, at the very least, its effects are supposed to be transient and reversible, said Ya-Chieh Hsu, a stem cell biologist at Harvard University who led the study.

The sympathetic nervous system helps mobilize many biological responses, including increasing the flow of blood to muscles and sharpening mental focus. But the researchers found that in some cases the same system of nerves permanently depleted the stem cell population in hair follicles.

The findings provide the first scientific link between stress and hair graying, Dr. Hsu said.

Stress affects the whole body, so the researchers had to do some sleuthing to figure out which physiological system was conveying its effects to hair follicles.

At first, the team hypothesized that stress might cause an immune attack on melanocyte stem cells. They exposed mice to acute stress by injecting the animals with an analogue of capsaicin, the chemical in chili peppers that causes irritation. But even mice that lacked immune cells ended up with gray hair.

Next, the scientists looked at the effects of the stress hormone cortisol. Mice that had their adrenal glands removed so they couldnt produce cortisol still had hair that turned gray under stress.

The system responsible for the appearance of silvery strands turns out to be the sympathetic nerves that branch out into each hair follicle in the skin.

The researchers found that the sympathetic nerve cells released a neurotransmitter called noradrenaline that was taken up by nearby melanocyte stem cells. Then a series of events unfolded in quick succession: The melanocyte stem cells proliferated and turned into specialized pigment-producing cells, which abandoned their niche near the base of the follicle and left the hair without a source of pigmentation.

In Dr. Hsus study, acute stress depleted the entire melanocyte stem cell population in mice in just five days. The researchers also found that, in petri dishes, noradrenaline prompted human melanocyte stem cells to proliferate, suggesting that the same acceleration of hair graying occurs in people, too.

I was amazed by how dramatic this change is, said Mayumi Ito, a biologist at the New York University School of Medicine who was not involved in the study. In her own research on aging mice, the graying process was gradual: The depletion of melanocyte stem cells led first to a few salt and pepper strands and then to gray or white fur, much as humans begin to see more white hair as they get older.

Dr. Itos team also found that the graying process in mice could be halted with drugs known as CDK inhibitors, which stop the proliferation of stem cells, or by blocking the release of noradrenaline.

The findings underscore the consequences of triggering a survival mechanism when the situation isnt life-threatening.

Stress is a normal part of life, but there are situations where stress is helpful and situations where it is detrimental, said Subroto Chatterjee, a biologist at Johns Hopkins University who studies the effects of stress on the cells in blood vessels.

Other studies have shown that stress is just one factor affecting how quickly hair goes gray, Dr. Chatterjee said. Genes and diet play a big role as well.

In a 2018 study, Dr. Chatterjee and his colleagues found that mice placed on the equivalent of a Western diet high in fat and cholesterol not only developed inflamed arteries, they also started going gray and experiencing hair loss. (The team also found a way to halt the process.)

But the new study is an important step toward understanding the role of stress on various tissues.

If we can know more about how our tissues and stem cells change under stress, we can eventually create treatments that can halt or reverse its detrimental impact, Dr. Hsu said.

Read more:
Stress Really Does Make Hair Go Gray Faster - The New York Times

Recommendation and review posted by Bethany Smith

Point blank: Aging is a part of life. With each passing second, minute, and day, we age a little bit more. While you may not notice the signs of aging right away, there will come a day when you look in the mirror only to notice 11s and crows feet staring back at you. Of course, if you implement a quality anti-aging skincare routine before then, it may be years before you notice such things.

Intrigued? We thought you might be. Thats why we tapped some of the industrys top dermatologists to share their top 10 anti-aging skincare ingredients. By committing these ingredients to memory and adding them into your routine, youll be able to pause the clock of visible aging while making way for your bounciest, most beautiful skin yet. You can thank us later.

While there are many anti-aging ingredients on the market, dermatologists share that the following 10 are the most effective for fast-acting results.

Alpha- and beta-defensins are natural immune proteins that have been shown in in vitro studies to activate stem cells in the hair follicle, which typically helps with wound healing of the skin, says Yunyoung Claire Chang, M.D., a board-certified cosmetic dermatologist. These defensins have been shown to be effective in a new skincare product, called DefenAge. One multi-center, blinded controlled trial published in the Journal of Drugs in Dermatology in 2018 evaluated 44 patients using this new skincare product, demonstrating that this product improves brown spots and skin evenness, improves the appearance of wrinkles, and reduces visible pores. She continues, noting that the product has retinol-like effects without the inflammation associated with retinol.

As you may have read in our recent deep dive into bakuchiol, the ingredient is well-known for being a gentle (yet effective) retinol alternative. These findings were confirmed in a 2014 study published in the International Journal of Cosmetic Science, where researchers found that bakuchiol was able to stimulate collagen production in vivo, which 12-week application improved texture, tone, photo-damage, and more. While it has many of the same benefits of retinol, Dr. Chang says the most notable quality is that bakuchiol has less of the drying and irritating side effects of retinol, while still being just as effective.

Youve likely seen ceramides called out on many of the labels on the skincare products already in your routine. Thats because ceramides are intensely hydrating and incredibly notable for anti-aging.

Ceramides are a natural lipid that helps protect our skin barrier and seal in moisture. As we mature, the ceramide levels in our skin decrease, leading to drier, more sensitive skin, Dr. Chang explains. Dry skin also worsens the appearance of fine lines and uneven skin texture. Replacing ceramides using topical skincare is important to keep it hydrated, protected, and smooth.

Ginseng might be considered a Korean delicacy for consumption, but were here to let you in on a little secret: It works wonders topically for your complexion, as well. Panax ginseng and ginsenosides are promising in preventing skin aging, Dr. Chang explains. Ginseng extract has been found in studies to protect against UVB-induced skin aging, reduce wrinkles, and increase moisture in the skin. Though, its worth noting that most ginseng skincare studies have been small and need to be corroborated with larger clinical trials.

Take it from someone with sensitive skin who loves a gentle exfoliation: Glycolic acid is an alpha hydroxy acid (AHA) gorgeous skin dreams are made of. Dr. Chang supports this notion, explaining that glycolic acid exfoliates the top layers of the skin to improve skin texture and tone. Glycolic acid also has additional anti-aging benefits, including fighting UV-induced inflammation, lightening brown spots, and stimulating collagen, she adds. With glycolic acid, the higher the concentration of the product, the stronger its effects (and side effects). As such, its best to leave the higher concentrations of glycolic acid to professional use during in-office facials and treatments.

In some cases, glycolic acid (despite being fairly gentle) can be too irritating for super-sensitive skin. In these cases, you can reach for lactic acid, another AHA thats incredibly effective at resurfacing the skin.

Courtesy of First Aid Beauty

Green tea might be a super popular beverage, but its also a stellar choice for reversing the clock on your complexion. According to Dr. Chang, green tea is an abundant source of polyphenols that can help protect the skin against UV-induced skin aging and skin cancer. It has antioxidant, anti-inflammatory, and anti-wrinkle properties, she adds.

Courtesy of Innisfree

Niacinamide, also known as vitamin B3, is a water-soluble vitamin that has been shown to have anti-inflammatory and anti-aging properties, Dr. Chang explains, noting that it helps calm red, inflamed, or irritated skin. Whats more, the hydrating ingredient helps protect the lipid barrier and keep the moisture barrier intact which helps heal dry skin and prevent seasonal flaking. It has also been shown to increase collagen production as well as inhibit melanosome transfer from melanocytes to keratinocytes, allowing lightening of dark spots, Dr. Chang adds. In other words, its a multi-tasker that deserves a spot in your anti-aging routine.

Courtesy of The Ordinary

Retinoids are a derivative of vitamin A and are one of the longest-studied anti-aging ingredients. Retinoids have a long track record and clinical studies since the 1980s to back its evidence for preventing and treating skin aging, Dr. Chang explains. Retinoids increase skin cell turnover, diminish brown spots, and stimulate collagen to prevent fine lines and wrinkles.

While retinoids are undoubtedly effective, its worth noting that some versions can cause dryness and irritation, especially for those with dry or sensitive skin. Therefore, its best to start with a low percentage retinol (like 0.025 percent) before working yourself up to a stronger dose, prescription retinoid or Retin-A (like 0.5 to 2 percent).

Even when starting off with low percentages, Dr. Chang points out that retinoids tend to be drying and irritating, especially with initial use. It is important to start slow, using a small pea-size amount over the face, she says. I recommend starting two or three times per week at nighttime, and increasing the frequency of use slowly as tolerated.

Additionally, Dr. Chang says that retinoids and glycolic acid, especially when used together, may cause excessive dryness and irritation. That said, its best to choose between the two instead of trying to use them simultaneously.

Courtesy of Neutrogena

Sun protection is the most critical part of your anti-aging skincare routine, Dr. Chang emphasizes. Sun exposure not only causes skin burning and skin cancer but is the main culprit for accelerated skin aging. Whats more, she adds that UV exposure forms free radicals, increases brown spots, and breaks down collagen to form fine lines, wrinkles, and skin laxity. This process, termed photo-aging, is absolutely preventable with the appropriate use of sun protection and broad-spectrum sunscreen, she explains, noting that she recommends mineral sunscreens with SPF 30 or greater, including zinc oxide and titanium dioxide. Mineral sunscreens sit on the surface of the skin and act as a barrier to both UVA and UVB rays rather than being absorbed into the skin, she explains. Because it isnt absorbed into the skin, there is a lower risk of allergic reactions and it is safe in pregnant females.

And remember: Regardless of the sun protection you opt for, reapplication every few hours is key.

Vitamin C renowned for its powerful antioxidant properties and the ability to affect so many aspects of aging. For starters, adding vitamin C into your skincare routine can lead to a brighter complexion. Whats more, Dr. Chang points out that the potent ingredient can act as a free radical scavenger to neutralize oxidative damage to the skin and stimulate collagen for fine line prevention.

The biggest thing to remember when adding vitamin C to your anti-aging routine is that the ingredient is very unstable. As a result, its important to look for stabilized formulations found in opaque, air-tight bottles.

Whats more, Dr. Chang notes that some formulations of antioxidant serums containing vitamin C may irritate or cause acne for some people, so it is important to find which products work best for your skin. This may take some trial and error (or, better yet, the advice of a derm), but it will be well worth it in the long run.

Great! So now that you know which skincare ingredients to keep on your radar, heres what else you need to know about how to use them.

The anti-aging skin type debate:

After reading about these anti-aging ingredients, you might be wondering which will be best for your skin type. While some are notedly more tolerated by some specific skin types (as mentioned above), its important to remember that skincare is subjective based on your skin type and the products already in your routine.

undefined

At the end of the day, she says its not so much the skin type as what you are trying to address. For example, retinoids help to rejuvenate at the cellular layer, she begins. Glycolic acids helps to increase cell turnover and exfoliation.

When to add anti-aging ingredients into your skincare routine:

As much as wed like to tell you exact dates down to the day as to when to incorporate these ingredients into your routine, its simply not realistic given that skin aging is subjective and varies from person to person. However, considering all of these ingredients are preventative, Dr. Chang says that its best to start noticing them before or shortly after you start to notice signs of skin aging. I recommend starting anti-aging skincare in your 20s or early 30s, she adds. Some of these ingredients can be started even earlier (i.e. retinoids in teenagers with acne).

How to add anti-aging ingredients into your skincare routine:

Now, we know what youre thinking: How hard could it be? Well, if you try to add all 10 of these ingredients into your routine at once, youll seeand it wont be pretty. Since these ingredients are active, its important to ease them into your routine to avoid any sort of adverse effects.

I always recommend starting anti-aging ingredients one by one, to avoid any skin reactions or excessive irritation, Dr. Chang says. Start with a test spot before applying new products over your whole face. If one anti-aging product is tolerated, you can slowly add another one into the regimen. Additionally, she notes that not every person needs to use all of these ingredients, as many of the benefits overlap and using too many products can sometimes do more harm than good. I recommend consulting your board-certified dermatologist to develop a skincare plan tailored to your skin needs, she shares.

Head-to-toe anti-aging treatments:

If you, like us, are a big believer in the beauty of cosmetic anti-aging treatments, like lasers and injectables, you might be wondering if you should supplement your anti-aging skincare routine with these in-office offerings. Considering most topicals can only penetrate the top-most layers of skin (unless, of course, its an epigenetic formulation), opting for treatments geared towards underlying causes of expression can be more effective for more noticeable results. For example, board-certified dermatologistJennifer MacGregor, M.D., says that Botox can smooth crepey texture in addition to lines (on the chest, for example) and can also smooth neck bands (hi, tech neck)something a cream alone may not be able to do.

Chang expands on this, noting that, As we mature, we lose fat and collagen in our face, leading to loose, sagging or hollowed skin. Filler injections can help replace this volume and collagen in areas where topical anti-aging products would have little to no efficacy. Additionally, she points out that brown spots and photo-aging are often due to deeper pigment deposits which topicals cannot reach. Laser treatments can more effectively lighten or eliminate brown spots and signs of photo-aging, she explains. Resurfacing laser treatments, like Fraxel dual, and skin tightening treatments, like Ultherapy, can go deeper than any topical can to stimulate collagen, making these treatments essential in the anti-aging process [from head to toe].

Read more here:
The only anti-aging skin care guide you'll ever need - Yahoo Lifestyle

Recommendation and review posted by Bethany Smith

By Simon Coghlan and Kobi Leins

A remarkable combination of artificial intelligence (AI) and biology has produced the world's first "living robots."

This week, a research team of roboticists and scientists published their recipe for making a new lifeform called xenobots from stem cells. The term "xeno" comes from the frog cells (Xenopus laevis) used to make them.

One of the researchers described the creation as "neither a traditional robot nor a known species of animal," but a "new class of artifact: a living, programmable organism."

Xenobots are less than 1mm long and made of 500-1000 living cells. They have various simple shapes, including some with squat "legs." They can propel themselves in linear or circular directions, join together to act collectively, and move small objects. Using their own cellular energy, they can live up to 10 days.

While these "reconfigurable biomachines" could vastly improve human, animal and environmental health, they raise legal and ethical concerns.

To make xenobots, the research team used a supercomputer to test thousands of random designs of simple living things that could perform certain tasks.

The computer was programmed with an AI "evolutionary algorithm" to predict which organisms would likely display useful tasks, such as moving towards a target.

After the selection of the most promising designs, the scientists attempted to replicate the virtual models with frog skin or heart cells, which were manually joined using microsurgery tools. The heart cells in these bespoke assemblies contract and relax, giving the organisms motion.

The creation of xenobots is groundbreaking.

Despite being described as "programmable living robots," they are actually completely organic and made of living tissue. The term "robot" has been used because xenobots can be configured into different forms and shapes, and "programmed" to target certain objects which they then unwittingly seek.

They can also repair themselves after being damaged.

Xenobots may have great value.

Some speculate they could be used to clean our polluted oceans by collecting microplastics.

Similarly, they may be used to enter confined or dangerous areas to scavenge toxins or radioactive materials.

Xenobots designed with carefully shaped "pouches" might be able to carry drugs into human bodies.

Future versions may be built from a patient's own cells to repair tissue or target cancers. Being biodegradable, xenobots would have an edge on technologies made of plastic or metal.

Further development of biological "robots" could accelerate our understanding of living and robotic systems. Life is incredibly complex, so manipulating living things could reveal some of life's mysteries and improve our use of AI.

Conversely, xenobots raise legal and ethical concerns. In the same way they could help target cancers, they could also be used to hijack life functions for malevolent purposes.

Some argue artificially making living things is unnatural, hubristic or involves "playing God."

A more compelling concern is that of unintended or malicious use, as we have seen with technologies in fields including nuclear physics, chemistry, biology and AI.

For instance, xenobots might be used for hostile biological purposes prohibited under international law.

More advanced future xenobots, especially ones that live longer and reproduce, could potentially "malfunction" and go rogue, and out-compete other species.

For complex tasks, xenobots may need sensory and nervous systems, possibly resulting in their sentience. A sentient programmed organism would raise additional ethical questions. Last year, the revival of a disembodied pig brain elicited concerns about different species' suffering.

The xenobot's creators have rightly acknowledged the need for discussion around the ethics of their creation.

The 2018 scandal over using CRISPR (which allows the introduction of genes into an organism) may provide an instructive lesson here. While the experiment's goal was to reduce the susceptibility of twin baby girls to HIV-AIDS, associated risks caused ethical dismay. The scientist in question is in prison.

When CRISPR became widely available, some experts called for a moratorium on heritable genome editing. Others argued the benefits outweighed the risks.

While each new technology should be considered impartially and based on its merits, giving life to xenobots raises certain significant questions:

Lessons learned in the past from advances in other areas of science could help manage future risks, while reaping the possible benefits.

The creation of xenobots had various biological and robotic precedents. Genetic engineering has created genetically modified mice that become fluorescent in UV light.

Designer microbes can produce drugs and food ingredients that may eventually replace animal agriculture.

In 2012, scientists created an artificial jellyfish called a "medusoid" from rat cells.

Robotics is also flourishing.

Nanobots can monitor people's blood sugar levels and may eventually be able to clear clogged arteries.

Robots can incorporate living matter, which we witnessed when engineers and biologists created a sting-ray robot powered by light-activated cells.

In the coming years, we are sure to see more creations like xenobots that evoke both wonder and due concern. And when we do, it is important we remain both open-minded and critical.

Simon Coghlan is a senior research fellow in digital ethics at the School of Computing and Information Systems, University of Melbourne.Kobi Leins is a senior research fellow in digital ethics at the University of Melbourne.

Disclosure statement: The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Reposted with permission from The Conversation.

Related Articles Around the Web

Original post:
Scientists Combine AI With Biology to Create Xenobots, the World's First 'Living Robots' - EcoWatch

Recommendation and review posted by Bethany Smith